

**ECU BOARD OF TRUSTEES**  
**March 17, 2020**

**M I N U T E S**

The ECU Board of Trustees met via conference call originating from the campus of East Carolina University on March 17, 2020. This meeting was rescheduled from February 7, 2020 due to a meeting of the UNC Board of Governors. Chair Vern Davenport called the meeting to order.

**ROLL CALL**

Mr. Davenport called on Megan Ayers, Assistant Secretary to the Board of Trustees, to call the roll.

Members Present

Vern Davenport  
Leigh Fanning  
Tom Furr  
Colin Johnson  
Max Joyner, Jr.  
Fielding Miller  
Angela Moss  
Bob Plybon  
Jason Poole  
Jim Segrave  
Vince Smith

Members Absent

**READING OF THE CONFLICT OF INTEREST STATEMENT**

In compliance with the State Government Ethics Act, Mr. Davenport read the conflict of interest statement and asked if anyone had a conflict of interest to disclose. Mr. Joyner identified a conflict of interest with an item coming from Athletics and Advancement Committee and the University Alcohol Policy.

**APPOINTMENT OF PARLIAMENTARIAN**

Mr. Davenport appointed Ms. Tannis Nelson to serve as parliamentarian for this meeting.

## **APPROVAL OF MINUTES**

Mr. Davenport asked for a motion to approve minutes from the November 22, 2019 regular meeting, as well as the December 13, 2020 special called meeting. Mr. Plybon moved to approve both sets of meeting minutes and the motion was approved unanimously.

## **EXECUTIVE SESSION**

Mr. Johnson moved that the board go into executive session to prevent the disclosure of confidential information under N.C. General Statutes §126-22 to §126-30 (personnel information); and the federal Family Educational Rights and Privacy Act; to consider the qualifications, competence, performance, character, fitness, or conditions of appointment of one or more prospective and/or current employees and/or to hear or investigate a complaint, charge, or grievance by or against one or more employees; to prevent the premature disclosure of an honorary degrees, honors, prizes or similar awards to consult with an attorney to preserve the attorney-client privilege. The motion was seconded by Mr. Fielding Miller and approved unanimously.

## **RETURN TO OPEN SESSION**

## **COMMITTEE REPORTS**

Upon resumption of open session, Mr. Davenport announced that all committee reports from February will not be read but will be entered into the minutes as part of the official record. Those reports are listed as “Attachment A.”

## **COMMITTEE RECOMMENDATIONS**

### **ATHLETICS & ADVANCEMENT**

Mr. Miller moved the board approve the Board of Visitors bylaws as presented in board materials but to include the follow language regarding membership: “no fewer than 40 appointed members and no more than 60 appointed members.” The motion was seconded and approved unanimously. The language of these revisions are included as “Attachment B.”

### **UNIVERSITY AFFAIRS**

Ms. Fanning moved the board approve the Alcohol Policy as presented in board materials. The motion was seconded without discussion and approved unanimously. Mr. Max Joyner recused himself from this vote. The Alcohol Policy is listed as “Attachment C.”

### **HEALTH SCIENCES**

At the recommendation of the Health Sciences Committee, Mr. Furr moved the board approve the appointment with tenure for Dr. Peter Koch in the Brody School of Medicine as presented in board materials. The motion was approved unanimously. This item is listed as “Attachment D.”

At the recommendation of the Health Sciences committee, Mr. Furr moved that the board approve the appointment with tenure for Dr. Maranke Koster in the Brody School of Medicine as presented in board materials. The motion was approved unanimously. This item is listed as “Attachment E.”

## **FINANCE & FACILITIES**

At the recommendation of the Finance and Facilities committee, Mr. Plybon moved the board approve the request to delegate authority from the Board of Trustees to the Chancellor, in consultation with the Board of Trustees Finance and Facilities Committee Chair, to approve non-General Fund repair and/or renovation projects whose cost is expected to be less than \$750,000 and report at each Board of Trustees meeting actions taken since the last meeting. The motion was approved unanimously. This item is listed as “Attachment F.”

## **NEW BUSINESS**

### **RESOLUTION REGARDING HOUSE BILL 966**

Mr. Smith and Michelle Brooks presented a resolution regarding House Bill 966. Mr. Smith moved the board support the resolution as presented in board materials. The motion was seconded by Angela Moss and the board voted in favor of the resolution with the exception of Mr. Colin Johnson. Mr. Johnson requested the record to reflect that he did not vote. The text of the resolution is listed as “Attachment G.”

## **COVID-19 UPDATE**

Interim Chancellor Ron Mitchelson provided an update to the board on the COVID-19 pandemic and ECU’s response. ECU is responding to the pandemic based on UNC System guidance. In an effort to reduce spread across campus, all dorms on campus on campus are closed and students have been urged to go home.

## **CHANCELLOR SEARCH**

Mr. Davenport announced the Chancellor Search Committee is scheduled to hold the third committee meeting on Monday, March 23. Due to COVID-19, there may be delays in the search process. Mr. Davenport also reminded the board on the need for confidentiality as the search process moves into next steps.

## **ADJOURNMENT**

Having no other business to come before the board, Chairman Davenport adjourned the meeting.

**Respectfully submitted,**

Megan Ayers  
Assistant Secretary to the Board

---

---

**Minutes**  
**Athletics & Advancement Committee**  
**February 6, 2020**

The Athletics and Advancement Committee met in regular session on February 6, 2020.

The meeting was opened with the reading of the Conflict of Interest Statement.

The minutes from the November 2019 meeting were approved.

Athletic Highlights

Mr. Jon Gilbert opened his presentation by reporting that January Pirate Club fundraising figures are up with a year-to-date deficit of \$43,227. January athletic non-annual fund figures are down by \$81,338; however, the year-to-date total is \$3,401,928.

Mr. Gilbert shared that football season ticket sales kicked off earlier this year than last with varying options for consumers. The projected target is 16,000 season ticket holders. Last year's sales were 14,097. Mr. Gilbert also reported that Men's basketball season tickets sales increased over last year but the targeted goal was not met. Individual game tickets have been trending well.

Athletic expenses compared to budget is tracking well while athletics revenue compared to budget is down \$65,347 and down \$682,793 year-to-date. This deficit is anticipated to remain for the remainder of the year. Mr. Gilbert assured the board that there are savings in multiple areas where funds can be pulled to assist the revenue line. Projected aggressive ticket sales will also benefit the revenue line.

Fourteen teams had a cumulative GPA of 3.0 and 13 teams had a semester GPA of 3.0.

Licensing sales are up \$125,000 over last year.

The structure of the Pirate Club Executive Director position is currently being assessed and the hope is to continue with an interim through this Spring.

Mr. Gilbert provided the following update on athletic facilities:

- Minges concourse floor is complete
- Softball batting cage has been enclosed
- Control Room at Dowdy Ficklen stadium should be complete by August 2020

The Pigskin Pig-out is scheduled for April 17-18 and more information will be forthcoming.

The 2020 football season opener will be against Marshall University on September 5. This will be the 50<sup>th</sup> anniversary of the catastrophic plane crash. We will host many events to commemorate this tragic event.

Advancement Highlights

Mr. Chris Dyba reported that the East Campus is trending ahead with a year-to-date total of \$3.2M and West Campus has lost a little momentum potentially due to legislative issues and the recent retirement of a lead fundraiser. He also mentioned that the President of the Medical and Health Sciences Foundation, Dr. Mark Notestine, will be leaving next month. Mr. Dyba is working with Dr. Mark Stacey to determine who will serve as Interim President. He also noted that last year the MHSF raised \$8M and he hopes to reach that goal again this year.

Mr. Dyba then introduced Ms. Kendra Alexander as the new Associate Vice Chancellor for Development and afforded Ms. Alexander the opportunity to address the board.

Mr. Dyba shared that he recently traveled to California and while there, in collaboration with our alumni association, hosted two events (one in San Diego and one in LA) to engage with our alumni on the west coast.

#### Board of Visitors

Mr. John Cooper gave a quick recap of the BOV meeting held on 1/31/2020. A committee was developed to work on revisions to the bylaws. Ms. Linda Hofler and Ms. Wanda Montano presented the suggested updates which are outlined in your board material. A motion was made to accept the changes as presented with the modification on membership to specify no more than 60 members with at least 40.

Mr. Cooper reminded the board that there is a \$500 commitment in support of Access scholarships expected from all BOV members and he would be personally calling individuals who have not met their commitment.

#### Closed Session

The committee moved into closed session to discuss one naming opportunity and one athletic personnel matter. The naming opportunity and the athletic personnel matter were reviewed and approved for recommendation to the full board tomorrow.

The committee returned to Open Session and concluded.

###

Respectfully submitted,

Maha Banning  
University Advancement

**Report of ECU Board of Trustees Audit, Risk Management, Compliance, and Ethics Committee  
February 6, 2020**

**There are no items which require action by the full board**

**Committee Chair Comments**

I discussed the communications protocol for soliciting and receiving details about specific internal audit reports. I also noted the unique nature of the KPIs that the Audit Committee monitors.

**Operational Metrics Review**

The committee reviewed the operational metrics related to Internal Audit, Healthcare Compliance, and Athletics Compliance. Through December 31, Internal Audit is on pace for completion of the annual audit plan and auditor productivity. The dip in productivity rate for the month of December was expected due to the holiday break. University management had completed over 95% of the corrective actions that Internal Audit has followed up on since July 1. Athletics Compliance is exceeding the KPI for providing Rules Education sessions. Healthcare Compliance exceeded the KPIs for the number of billing education sessions and provider documentation reviews in November and December.

**State Auditor Presentation – Hon. Beth Wood**

State Auditor Wood briefed the committee on the University's annual financial statement audit for the fiscal year that ended on June 30, 2019. Auditor Wood explained that the University's financial statements were given a "clean opinion", which means that they are fairly stated and materially correct. She also reported that the audit revealed no internal control weaknesses that would have a material effect on the financial statements. Auditor Wood stressed the important role that the University's Internal Audit function serves in evaluating controls and detecting fraud. Ms. Wood stated that the University was not asked to make any corrections as a result of the state's audit. Kudos were given to the team in Administration and Finance for their great work.

**Internal Audit – Mr. Wayne Poole**

Mr. Poole updated the committee on the staffing in the Office of Internal Audit. The team currently has a vacant Audit Supervisor position which should be filled within the next month.

Based on my previous request, Mr. Poole briefed the committee on the results of two recently completed internal audits. Mr. Poole discussed the Investment Performance audit and the follow-up audit of Student Transit recommendations. I intend to ask for a briefing on selected internal audits at each committee meeting moving forward.

**Enterprise Risk Management – Vice Chancellor Sara Thorndike**

Dr. Thorndike shared the University's top risks matrix which details the University's top risks, the risk management process owner, and details on how and when each of the risk areas has been shared with this Board. We also received information on one of the top risk areas in Closed Session during yesterday's meeting.

Mr. Wayne Poole briefed the committee on an ERM Maturity Assessment that the Office of Internal Audit is currently engaged in with Dr. Thorndike and her team. The objectives of this engagement are to assess the maturity of the University's ERM program against an industry model, and to collect feedback from senior management, mid-level management, and Board of Trustees members on their perceptions of the ERM process and how it might be strengthened. Mr. Chairman, I respectfully ask that any Board members who are contacted please participate in surveys and/or interviews as part of this engagement.

Mr. Chairman, this concludes my report.



**East Carolina University | Board of Trustees  
Finance & Facilities | Main Campus Student Center | February 06, 2020  
Highlights**

Finance and Facilities Committee met on February 06, 2020.

**I. MINUTES**

- A. The Committee approved the minutes from the November 21, 2019 meeting.

**II. Review of Operational Metrics**

**III. ACTION ITEMS**

- A. Sara Thorndike, VC for Administration & Finance, requested approval of the Capital Project Delegation.

**IV. INFORMATION ITEMS**

- A. Sara Thorndike, VC for Administration & Finance, provided the Comprehensive Budget Report.
- B. Sara Thorndike, VC for Administration & Finance, provided the Approved EHRA Employee Salary Adjustments, pursuant to September 30, 2016 Expanded Authority.
- C. Sara Thorndike, VC for Administration & Finance, provided the Pension Report.
- D. Bill Bagnell, Associate VC for Campus Operations, provided information on the Designer Selections since the last Board Meeting.
- E. Bill Bagnell, Associate VC for Campus Operations, updated the Committee on Capital Projects.
- F. Bill Koch, Associate VC for Auxiliary Services, gave an update on Parking.
- G. Bill Koch, Associate VC for Auxiliary Services, and Chief Barnwell gave an update on the Annual Campus Safety Report.
- H. Sara Thorndike, VC for Administration & Finance, provided info on the new 1Card agreement with Wells Fargo.

Meeting adjourned at 2:28 pm.

**Health Sciences Committee  
February 6, 2020**

- Minutes from the November 21, 2019 meeting were approved.
- Dr. Mark Stacy reviewed the Health Sciences Division metrics that were selected for the dashboard. ECUP was budgeted to have a \$2.3M deficit through December. December's YTD loss was only \$300K, resulting in a \$2M positive budget variance. ECUP budgeted to receive an UPL (Upper Payment Limit) reconciliation payment of more than \$1.5M in December, that was not received until January. If received prior to the end of December, a \$3.5M positive budget variance would have resulted. Patient revenues were 6.2% better than budget, in part, due to some Medicaid retroactive payments for services provided in FY19 and due to higher productivity. The wRVU's generated through December were 795K resulting in a negative variance of 2.2%.
- Dr. Mark Stacy provided a Health Sciences Division update in which he discussed progress between the BSOM and Vidant Health in regard to governance changes, the funds flow analysis contract and operational adjustments. He also highlighted the work of each of the schools/colleges within the Health Sciences Division including the efforts toward suicide prevention and improving access to health care in rural and underserved areas.
- Dr. Greg Chadwick and Dr. Ron Tempel of the School of Dental Medicine presented an update on the school's points of pride. They highlighted the mission of the school in improving oral health, educating leaders/dentists and providing care in rural/under-resourced areas of NC. Students represent 85 NC counties and their student diversity is higher than the NC URM Practicing Dentists. The total 4-yr. tuition and mandatory costs is much lower than schools like MUSC, UTHSC, UNC and VCU. 93% of graduates practice in 56 different counties in NC. More than 110 US Military Veterans have received free dental care at the CSLC-Sylva. The School has been recognized as an Apple Distinguished School for the 5<sup>th</sup> consecutive year.
- Ms. Brianna Chavis-Locklear, a student in the School of Dental Medicine, shared her student experience at ECU. She is a student member of the Society of American Indian Dentists and a member of the Lumbee Tribe. She has played an active role in bringing an oral health and hygiene presentation called Lessons in a Lunch Box to her former school in the Prospect Community of Robeson County. Her goal is to bring positive change through oral health care to American Indians and other underserved North Carolinians. She stated that her experience has been phenomenal and the faculty and staff at the School of Dental Medicine have been like family. She is confident that ECU has prepared her for a future career in dental medicine.

Commented [BMI]: I don't know what this is....

**ECU BOT Health Sciences Committee Action:**

**Action Items from closed session to be announced in open session:**

**Health Sciences Committee  
February 6, 2020**

Closed Session Minutes from the November 21, 2019 meeting were approved.

*Request – The Board approve the following motions:*

I move that:

- The Board approve the appointment with tenure for Dr. Peter Koch in the Brody School of Medicine as presented in board materials and recommend this item to the full board for approval.
- The Board approve the appointment with tenure for Dr. Maranke Koster in the Brody School of Medicine as presented in board materials and recommend this item to the full board for approval.

**ECU Board of Trustees - University Affairs Committee**  
**February 6, 2020 - Main Campus Student Center – Room 249**

All Board Members were in attendance as well as Chancellor Ron Mitchelson, Jeff Popke, Mike Van Scott, Grant Hayes and Virginia Hardy

During the conflict of interest statement Max Joyner recused himself from the Alcohol Policy discussion due to his association with the ABC Board.

- **Three-minute Thesis**
  - Mary Farwell introduced a student named Felicia who presented on her research focused on infections when antibiotics won't work or worse that they obtain antibiotic resistant bacteria. She is looking at different forms of this to see why some bacteria stays alive longer and causes medical issues for many people.
  
- **Review of Operational Metrics**
  - Chancellor Mitchelson presented for Academic Affairs - on YTD, we are going to set a record for application of first year students and are focusing on yield. Tuition deposits are up about 20%. We do have lag on housing deposits right now, but still that number is up too. For transfer, we have a decrease in the number of apps, but our yield is still strong.
  - Dr. Hardy - For housing deposits, we are up about 140 YTD. Our counseling numbers are up right now.
  - Dr. Van Scott – research metrics from System are on track for hitting our goals.
  
- **Action Items**
  - **Alcohol Policy** – Chris Locklear shared the members of the Task Force results which created a University Policy for approval. The new policy which allowed ECU to sell alcohol at sporting events created some conflicts with the Alcohol Policy that was in place since 2014. The chancellor endorsed this in November 2019 and are asking the approval from the Board.
    - **Motion Made by Colin Johnson and seconded by Vince Smith – motion was approved without dissent.**
  
- **Informational Items**
  - **Transfer Students (Stephanie Whaley and Erica Hoyt)**
    - Stephanie shared that while we have seen some application numbers have gone down in recent years, we have maintained our transfer student yield. We are consistently higher for our ECU yield rate over the national average. Erica shared the demographics of ECU's current transfer group including age group, student credit hours, and academic summary (e.g. average GPA). About 1/3 of our transfer students want to complete their degrees at ECU online. She shared the top majors for transfer students to include management, industrial technology, nursing, education, marketing and communication. All of the top six offer an online option.

- Stephanie shared some of the national community college trends including declining enrollments due to decreasing HS graduates and many community colleges are relying on dual enrollments for their numbers. Every year since 2015, including NC Community Colleges, have declined in enrollment. In fact, only six community colleges of the 58 in NC have increased enrollment between Fall 2014 to Fall 2018. The top six ECU community college feeders have all seen decreases in enrollment, except for Wake Tech Community College.
- Stephanie shared the top five competitor schools that ECU loses students to including UNC Charlotte, NC State, UNC Wilmington, App State and UNC Greensboro. She shared how we are recruiting transfer students and how we are using “RaiseMe” to entice transfer students to come to ECU for positive performance. They can receive up to \$1,000 as long as they are Pell eligible.
- In the past, ECU had only two transfer employees to cover the entire state. Now we have six (with two vacant positions) that allows us to visit each community college and school each year and sometimes more frequently.
- Erica shared Pirate Promise and how it works at ECU. We now have agreements with 30 community colleges in NC (out of 58) signed up since Fall 2018 and includes many of our top feeder schools. If the student earns an associate degree along with a 2.5 GPA we guarantee admission to ECU and we will waive their application fee. So far, we have 84 students currently enrolled from Promise schools that are at ECU with 335 more that are actively engaged. We have 69 of those 335 that have applied or been admitted to ECU for summer/fall.
- Transfer students have different needs than freshman students and we need to make sure this path is smooth and easy.
- A future discussion may include re-visiting the transfer requirement at ECU.



**Board of Trustees  
Research & Economic Development Ad Hoc Committee | Main Campus Student Center  
February 06, 2020  
Highlights**

Research & Economic Development Ad Hoc Committee met on February 06, 2020

**Agenda**

**I. MINUTES**

- A. Research & Economic Development Meeting of November 21, 2019                      Action

**II. INFORMATION ITEMS**

- A. Mike Overton, Chair of the Greenville NC Alliance, gave an overview of the economic development organization serving eastern NC.

Meeting adjourned at 8:49 am.



TO: ECU Board of Trustees  
Athletics & Advancement Committee

FROM: ECU Board of Visitors

DATE: February 3, 2020

RE: ECU Board of Visitors Bylaw Revisions – Proposed

On January 31, 2020, the ECU Board of Visitors unanimously approved the recommended revisions to the Board of Visitors' bylaws. Please see below for a summary of those changes. Upon review, we are asking that the Board of Trustees amend the Board of Visitors bylaws as prescribed in that summary.

#### Summary of Proposed Revisions to the By-Laws

- Recommending changing the name of the document from "Charter" to "By-Laws." The Charter will continue to exist in its original form, as approved on March 18, 1994. All subsequent changes made to that document, are now encapsulated in a second document entitled "Amended and Revised By-Laws," to which all changes are applied.
- Recommending amending the size of the membership from 40 appointed members to "no more than 60 appointed members." This reverses the change in the 2018 bylaw revisions.
- Recommending reinstating the Mayor of the City of Greenville or designee and the Pitt County Commissioners designee to the ex-officio membership.
- Recommending a term of four years rather than the two-year terms. This also reverses the change made in 2018 bylaw revisions.
- Recommending removing the requirement that the Member be physically present for three successive meetings, and to permit telephonic participation. However, a member must be physically present for 1 meeting out of every 3 rolling meetings. Note, however, that physical presence at the meetings is preferred and highly recommended.

- Recommending adding language regarding excused absences to be at the discretion of the Chair.
- Recommending the establishment of a Nominating Committee and defines its scope of work to include the nomination of Members to the full board, as well as the Office Nomination Process.
- Recommending changing the number of terms an officer can be elected to a specific office from “for an unlimited number of terms” to “a second one-year term.”

Thank you for your consideration of these proposed revisions.



### By-Laws

The Board of Trustees of East Carolina University by action at a meeting held on March 18, 1994, has approved these By-laws providing as follows:

#### **ARTICLE I: Organization and Duration**

1. There is hereby created an unincorporated association to be known as the EAST CAROLINA UNIVERSITY BOARD OF VISITORS.
2. The association shall continue in existence at the pleasure of the East Carolina University Board of Trustees.

#### **ARTICLE II Purpose and Functions**

1. The EAST CAROLINA UNIVERSITY BOARD OF VISITORS shall be a service organization of East Carolina University.
2. In this role, the association shall have the following functions:
  - a. to educate members concerning the mission, programs, accomplishments, needs and aspirations of East Carolina University, and to assist in communicating and promoting them to the general public, governing bodies and other specific constituencies as requested by the Chancellor and the Board of Trustees, and;
  - b. to help keep the Board of Trustees and the Chancellor informed of the attitudes, opinions, concerns and expectations of alumni, supporters and stakeholders, with respect to East Carolina University; and
  - c. to energize and develop sustained personal support of and engagement in the programs and activities of ECU; and
  - d. to assist the Board of Trustees and Chancellor on special projects as may be delegated to this association from time to time.

## ARTICLE III Membership

1. The EAST CAROLINA UNIVERSITY BOARD OF VISITORS shall consist of no more than sixty (60) appointed members and eight ex-officio members with full participatory privileges, to include:
  - A member of the ECU Board of Trustees
  - Chancellor
  - Chair of the ECU Alumni Association, or designee
  - Chair of the ECU Foundation, or designee
  - President of the ECU Educational Foundation (Pirate Club), or designee
  - Chairman of the ECU Medical and Health Sciences Foundation, or designee
  - Mayor of the City of Greenville, or designee
  - Chairperson, Pitt County Board of County Commissioners, or designee
2. There shall be but one qualification for membership in the association: a willingness to help East Carolina University fulfill its general, educational, research, and service missions to maximize student success, serve the public and lead regional transformation.

Special consideration will be given to applicants that are ECU alumni and/or supporters of Pirate Nation. Board candidates should be familiar with and supportive of the mission, vision and values of the University. Candidates should show a commitment to all levels of diversity and inclusiveness and must be able to demonstrate strategic thinking and dedication to the core values, programs and activities of East Carolina University.

3. Members shall be appointed to the association by the Board of Trustees upon recommendation by the Chancellor. Nominations will be solicited from the Board of Trustees, the Board of Visitors, the Chancellor and the Chancellor's Executive Council.
  - a. The Executive Committee of the Board of Visitors will review nominations and will forward a formal slate of nominees to the Chancellor for consideration.
4. As terms expire, members shall be appointed annually before the July meeting of the Board of Trustees.
  - a. Each appointed member will serve one four (4) year term ending June 30th of the appropriate year.

- b. Any person initially appointed for less than a four (4) year term is immediately eligible for re-election to a four (4) year term.
  - c. All outgoing members will be eligible for reappointment to a second consecutive four (4) year term.
  - d. After the 2nd term, the member will be ineligible for re-election for a period of one year.
  - e. Any vacancy that occurs in the membership shall be filled for the balance of the unexpired term in the manner specified in paragraph 3 of this Article.
5. Upon the conclusion of a term of service on the ECU Board of Visitors, any member who has served in the capacity of Chair will be designated as an emeritus(a) member. Members Emeritus(a) will serve in an ex-officio capacity of the ECU Board of Visitors in perpetuity. This action will increase the total membership of the ECU Board of Visitors in accordance with the number of members holding emeritus(a) status. Attendance requirements do not apply to emeritus members.
6. There are attendance and philanthropic expectations associated with membership on the Board of Visitors.
  - a. If a member fails to be present for three (3) successive regular meetings of the Board of Visitors, unless excused by the Chair, his/her place as a member shall be deemed vacant.
  - b. Members may attend telephonically.
  - c. One meeting out of every 3 rolling meetings must be physically attended, or his/her place as a member shall be deemed vacant.
  - d. In addition, if any member fails to meet the philanthropic giving requirement for the Access Scholarships in the amount of \$500 annually, his/her place as a member shall also be deemed vacant.
7. Vacancies in membership may be declared by the Board of Trustees for any cause determined by the Board at their discretion.

#### **ARTICLE IV: Officers**

1. There shall be a Chair, a Vice Chair, and a Secretary of the association.
2. The officers of the association shall be appointed each July by the Board of Trustees on nomination by the Chancellor and upon recommendation of the full association.

3. Such officers shall serve until June 30 of the year following their appointment as officers. An officer may be re-appointed for a second one-year term. Any vacancy in an office shall be filled for the balance of the unexpired term in the manner specified in Article VI herein.

#### **ARTICLE V: Meetings**

1. Meetings of the association shall be called by its Chairman in consultation with the Chancellor, and shall normally occur three times a calendar year, with the calendar set in advance of June 30<sup>th</sup> of each year.

#### **ARTICLE VI: Nominations**

1. The association shall have a standing permanent committee known as the Nominating Committee.
2. The Nominating Committee of the association operates subject to the overall by-laws of the ECU Board of Visitors.
3. The Nominating Committee of the association will nominate Members to serve on the Board of Visitors, as well as the Officers of the association.
4. The Nominating Committee will consist of 5 members of the Board of Visitors, appointed by the Executive Committee of the Board of Visitors. Each Board of Visitors officer shall appoint 1 member each, and the remaining 2 members will be appointed by a majority of the officers.
5. Term of Service:
  - a. The Nominating Committee will serve a one-year term and may be re-appointed to a second one-year term.
  - b. If a Member of the Nominating Committee is elected to serve as an Officer of the Board of Visitors, their position on the Nominating Committee is terminated. The unexpired term will be filled by an appointment made by the remaining 4 members of the Nominating Committee.
6. Scope of Work: The Nominating Committee will perform the following functions:
  - (A) Membership of the Board of Visitors
    - i. Solicit from current members of the Board of Visitors, the Board of Trustees, and the Chancellor's Executive Council, nominations for individuals to serve as a Member of the Board of Visitors.

- ii. Review all nominations for service as a Member of the Board of Visitors.
  - a. Nominations shall be reviewed, and their qualifications and desire to serve will be assessed.
  - b. In selecting candidates for membership, the Nominating Committee shall consider demographic diversity, including, but not limited to geographic location, race, and gender, as well as representation by alumni from each of the University's academic units.
- iii. Manage and revise the Nominations Forms utilized in the nominations process.
  - a. Proposed revisions to the forms will be reviewed and approved by the Executive Committee and approved by the full Membership at its next meeting.
- iv. Maintain a database of potential candidates for membership.
- v. Make recommendations to the Board of Trustees for appointments to the Board of Visitors
  - a. Appointment slate is due to the Board of Trustees prior to their April meeting each year.

#### B. Officer Nomination Process

- a. The association's Nominating Committee shall, at the direction of the Chair of the association, solicit nominations for the Officer positions.
- b. Nominations will be solicited from the membership of the Board of Visitors for the positions of Chair, Vice Chair and Secretary of the Board of Visitors. Nominators should consider members who have demonstrated proven leadership, active participation, knowledge of the mission and aspirations of ECU and diversity of age, gender, ethnicity and geography.
- c. Candidates for office must have completed a minimum of two (2) years of service on the Board of Visitors.
- d. Nominations will be vetted thoroughly by the Nominating Committee, including, but not limited to, interviews with prospective candidates and assessing involvement from the membership.
- e. One month prior to the Spring meeting, the slate of recommendations from the Nominating Committee will be sent to the membership of the Board of Visitors for review.
- f. At the Spring meeting of the association, a formal vote will take place on the slate of officers to recommend to the Chancellor and to the Board of Trustees.

- g. Voting on this item will follow the protocol and parliamentary procedures stipulated in Robert's Rules of Order.
- h. Voting will occur via a written ballot, which shall permit nominations from the floor. If a member is attending telephonically, his/her vote will be recorded verbally in the open meeting.
- i. The elected Officers shall be sent to the Chancellor for concurrence and submission to the Board of Trustees.

## **ARTICLE VII Amendments**

- 1. This Charter may be amended at any time by action of the Board of Trustees.
- 2. Amendments may be made by the Board of Trustees on its own initiative or in response to suggestions made by the Chancellor or by the association.

## AMENDMENTS MADE TO THE BYLAWS

1. The East Carolina University Board of Visitors be expanded by ten members and set appointments be made at the next appointment cycle.

Approved by the Board of Trustees on December 6, 1996.

2. Article III, 4. Changed the word "ten" deleted and the sentence read, "As terms expire, members shall be appointed annually at the July meeting of the Board of Trustees.

Authorized by Dr. James LeRoy Smith, Assistant Secretary, East Carolina University Board of Trustees February 1, 1999.

3. The suspension of the Board of Visitors Charter stipulation that Board of Visitors be elected in July so that we can conduct that election today and also that we hereby modify that charter to indicate that such elections take place prior to July 1st of each year.

Approved by the Board of Trustees on May 14, 1999.

4. Upon the conclusion of a term of service on the ECU Board of Visitors, any member who has served in the capacity of Chair will be designated as an emeritus(a) member. Members Emeritus(a) will serve in an ex-officio capacity of the ECU Board of Visitors in perpetuity. In the event the person is appointed to a subsequent term by regular appointment, emeritus(a) status will be held in abeyance pending conclusion of the regular term. This action will increase the total membership of the ECU Board of Visitors in accordance with the number of members holding emeritus(a) status.

Approved by the Board of Trustees on December 16, 2005.

5. If for any reason other than ill health or service in the interest of the State or nation, a member fails to be physically present for three (3) successive regular meetings of the Board of Visitors, his/her place as a member shall be deemed vacant.

Approved by the Board of Trustees on July 25, 2006.

6. Expanded the board from 50 to 60 members. In addition, allowed outgoing members to be elected to a 2nd consecutive four year term.

Approved by the Board of Trustees on February 26, 2010.

7. Expanded the board from 60 to 70 members

Approved by the Board of Trustees on February 14, 2014

8. There are attendance and philanthropic expectations associated with membership on the Board of Visitors. If for any reason other than ill health or service in the interest of the State or nation, a member fails to be physically present for three (3) successive regular meetings of the Board of Visitors, his/her place as a member shall be deemed vacant. In addition, if any member fails to meet the philanthropic giving requirement in the amount of \$500 annually, his/her place as a member shall also be deemed vacant.

Approved by the Board of Trustees on July 15, 2016

9. Revised Article II - Expand the definition of the purpose and functions of the BOV. This revision ties the purpose and function of the BOV with the ECU Strategic Plan and more clearly defines what the membership should "do" as members, while still allowing the Chancellor and Board of Trustees the flexibility to use the BOV as needed strategically

Revised Article III – Membership – The membership of the BOV is going from 60 to 40 appointed members. That reduction will happen over the course of the next 2-3 years through natural attrition (no one will be asked to step down or vacate their seat). There is also a revision to modify the number of ex-officio members from 9 to 6, keeping the Chancellor, the Board of Trustee representative, and representatives from each of the four university foundations.

Revised Article III – Term Limits. BOV member's term limits are now 2 years. A BOV member could be appointed to one two year term, then be eligible for reappointment to a 2nd two year term, for a total of 4 years of service.

Revised Article IV – Officer Nomination Process. This section includes the steps this body would take to recommend a slate of officers to the Board of Trustees. This

would include using a nomination committee of the BOV and assessing leadership nominations from the entire BOV. The BOV would formally vote on a slate of officers to recommend to the Trustees at their spring meeting.

Approved by the Board of Trustees on November 2, 2018

10. Amendments approved at February 2020 Board of Trustees meeting will be incorporated herein.

**University Alcohol Policy****Version 3 (Revision)**

**Policy** POL07.30.04

**Title** University Alcohol Policy

**Category** Finance, Operations and Auxiliary Services

**Sub-category** Facilities

**Authority** Board of Trustees

**History** Issued: 1985. Revised; 1995; Placed in University Policy Manual after EXPEDITED REVIEW, transitioned without substantive change from prior version, March 25, 2013; Revised Interim approved by ECU Board of Trustees October 9, 2014; Revised and approved by the ECU Board of Trustees,

**Contact** Associate Vice Chancellor of Student Involvement & Leadership

**Related Policies** N/A

**Additional References** UNC Code Appendix 1 – Delegations of Duty and Authority to Boards of Trustees: (C. Personnel, XII. Students, XII. Athletics, XVI. Facilities) (<http://www.northcarolina.edu/apps/policy/index.php?pg=vs&id=s4210>)

Form for Requesting Permission to Serve Alcohol  
(<http://www.ecu.edu/cro/policiesandProcedures.cfm>)

N.C. General Statute 18B – Regulation of Alcoholic Beverages  
([http://www.ncga.state.nc.us/EnactedLegislation/Statutes/HTML/ByChapter/Chapter\\_18B.html](http://www.ncga.state.nc.us/EnactedLegislation/Statutes/HTML/ByChapter/Chapter_18B.html))

N.C. ABC Commission website (<http://abc.nc.gov/>)

City of Greenville Ordinance No. 358 and 360  
(<http://www.pittcountync.gov/bcc/ordinance/planning/14.pdf>)

ECU REG01.15.11 Possession, Consumption and Sale of Alcoholic Beverages,  
(<https://www.ecu.edu/prr/01/15/11>)

ABC Board Permit Process (<https://abc.nc.gov/Search/Permit>)

ECU Central Reservations Office (<https://cro.ecu.edu>)

---

## **1. LEGAL CONTEXT**

The sale, service, possession, and consumption of alcoholic beverages are regulated by North Carolina General Statutes, Greenville City Code and University Policies. All members of the University community are obligated to obey these laws, policies and ordinances. The University does not have the right to alter the laws and ordinances or secure exemption from them. The University may be required to participate in the enforcement of the laws and ordinances.

## **2. DEFINITION OF UNIVERSITY JURISDICTION**

Jurisdiction of the University alcohol policy shall extend to every student currently enrolled for course work at East Carolina University and to currently employed faculty and staff. It shall also extend to properties owned by the University or leased by the University for the University's use.

## **3. LEGAL REQUIREMENTS OF THE STATE OF NORTH CAROLINA**

In summary, North Carolina General Statutes as stated in the Alcoholic Beverage Control laws provide:

### **3.1 Sale of alcoholic beverages**

3.1.1 State law prohibits the sale of any alcoholic beverage on the university campus by any person, organization, or corporation on the campus of the university, except by a hotel, a nonprofit alumni organization with a mixed beverages or special occasion permit, or at a stadium, athletic facility, or arena on campus if approved by the Board of Trustees with an appropriate permit.

### **3.2 Possession and consumption of alcoholic beverages**

3.2.1 It is unlawful for any person less than twenty-one (21) years of age to consume, possess, and/or purchase malt beverages, unfortified wine, fortified wine, spirituous liquor or mixed beverages.

### **3.3 Sale to or purchase by underage person**

3.3.1 It is unlawful for any person to sell or give any alcoholic beverage to a person less than 21 years old.

3.4 Aider and Abettor

3.4.1 It is unlawful for any person to aid or abet another in violation of 3.2 above.

3.5 Fraudulent Use of Identification

3.5.1 It is unlawful for any person to obtain or attempt to obtain alcoholic beverages by using or attempting to use:

3.5.1.1 A fraudulent or altered driver's license; or

3.5.1.2 A fraudulent or altered identification document other than a driver's license; or

3.5.1.3 A driver's license issued to another person; or

3.5.1.4 An identification document other than a driver's license issued to another person.

3.6 Allowing Use of Identification

3.6.1 It is unlawful for any person to allow the use of his or her driver's license or any other identification document by any person who violates or attempts to violate 3.2 above.

3.7 Conviction Report Sent to Division of Motor Vehicles

3.7.1 A violation of 3.2, 3.3, 3.4, 3.5 or 3.6 may result in the court filing a conviction report with the Division of Motor Vehicles. Upon receipt of the conviction report the Division may revoke the person's license for a period of one year; there is no limited driving privilege.

**4. GREENVILLE ORDINANCE**

4.1 **SEC. 12-1-2 CONSUMPTION OF ALCOHOLIC BEVERAGES IN PUBLIC.** (A) Malt beverages and unfortified wine; general prohibition. It shall be unlawful for any person to consume a malt beverage or unfortified wine on any public street in the city or any public place owned, occupied, or controlled by the city. It shall be unlawful for any person to possess an open container of malt beverage or unfortified wine on any public street in the city or any public place owned, occupied, or controlled by the city. (Greenville Ordinance No. 358 and 360)

**5. UNIVERSITY POLICIES ON POSSESSION, CONSUMPTION, AND SALE OF ALCOHOLIC BEVERAGES:**

5.1 Prohibition on possession, consumption, and sale of Alcoholic Beverages

5.1.1 Possession, Consumption, and Sale of Alcoholic Beverages are prohibited (a) for all persons under the age of 21; (b) in areas of classrooms being used for instructional purposes; and (c) in all other buildings, facilities, and grounds of the University except in instances described in provisions 5.2 below, or in other areas when and as approved by the Chancellor or his or her designee.

5.1.2 In any instance where the sale of alcoholic beverages is allowed in this University Alcohol Policy, the party responsible for the sales must obtain the appropriate N.C. Alcoholic Beverage Commission permit(s), allowing the sale, in advance of the event for use by the University's official catering vendor or other University approved bartenders. It is suggested that such permits must be applied for 45-60 days in advance of the event in order to assure receipt in time for the event to occur.

5.1.3 Events for which an appropriate N.C. ABC permit must be obtained would include, but are not limited to, any instance where alcoholic beverages are sold utilizing a "cash bar" or where a ticket or other form of admission is sold to an event which includes "drink tickets" or the service of alcoholic beverages as part of a meal or reception.

## 5.2 Permitted Possession, Consumption, and Sale of Alcoholic Beverages

**5.2.1 Residence Halls and Surrounding Areas:** Possession and Consumption of Alcoholic Beverages by those 21 years and older are permitted if those persons who use or possess alcoholic beverages shall do so legally as prescribed by the laws of the state of North Carolina, within the regulations of East Carolina University, and in a manner that does not disrupt the lives of others. A student whose conduct is outside these parameters will be subject to university disciplinary proceedings pursuant to the ECU Student Code of Conduct.

5.2.1.1 Students who are 21 years of age or older are allowed to possess and consume in their own rooms or in the room of another resident who is 21 or older. Guests who are 21 or older may consume alcohol only in the room of a resident who is 21 or older. Neither residents nor guests may possess or consume alcohol in the room of any underage resident. Students and guests who are 21 or older and who possess or consume alcohol in a room where an underage guest or resident is also possessing, or consuming alcohol are violating the alcohol policy.

5.2.1.2 Common sources of alcohol (i.e., kegs, party balls, punch bowls, etc.) are prohibited in residence halls or surrounding areas.

5.2.1.3 Residents are not permitted to have a party in their room where alcoholic beverages are served. A party is defined as being more than six people in a room, regardless of age.

5.2.1.4 The resident(s) of the room are responsible for the behavior of the people in the room, including the guests.

5.2.1.5 Manufacturing of alcoholic beverages is prohibited in the residence halls.

5.2.1.6 The possession of alcohol is prohibited in the room of any underage students.

**5.2.2 Non-Residential University Property:** Possession and consumption of alcoholic beverages in nonresidential buildings on University property and areas other than the private rooms in University housing facilities are prohibited except as allowed under provisions of the University Regulation regarding the Possession, Consumption and Sale of Alcoholic Beverages, REG01.15.11.

**5.2.3 Student Organizations:** Student Organization requests for permission must be obtained from the Associate Vice Chancellor of Student Involvement and Leadership. Requests must be made at least three weeks in advance of the event and during the regular office hours.

5.2.3.1 Space reservations must be made with the University Central Reservations Office in the Main Campus Student Center (328-4731) and should be submitted at least three (3) weeks in advance.

5.2.3.2 If the request for Campus Approval of Alcoholic Beverage use is granted, then the Associate Vice Chancellor of Student Involvement & Leadership ensures a copy of the form is provided to ECU Campus Police.

5.2.3.3 An adviser or staff member representing a student organization and approved by the Associate Vice Chancellor must be in attendance for the duration of any function where alcoholic beverages are served.

5.2.3.4 The officers of the sponsoring organization must ensure adequate safeguards are in place for compliance with federal, state, and municipal ordinances and laws and all University policies during events at which alcohol is served or consumed.

5.2.3.5 Alcoholic beverages must be purchased by the sponsoring organization and distributed by a bartender through the university's official catering services.

5.2.3.6 The purchase of alcoholic beverages with student fees is prohibited.

### **5.3 Discipline and Enforcement**

5.3.1 Infractions of the University policy are grounds for University disciplinary actions, which may (at the discretion of the University) be adjudicated at the University level in addition to being adjudicated in the court system.

5.3.2 In circumstances where alcohol is indicated to be contributing factor relating to any violation of any applicable law, policy or regulation, students, faculty, and staff may be required to participate in an alcohol education program.

5.3.3 A person who violates state or local law or University policy while intoxicated remains fully responsible for his or her actions and the consequences thereof. The consumption of alcohol and/or the results of such consumption are never considered to compromise personal responsibility or accountability.

5.3.4 The sponsoring organization and university designated representative shall be responsible for the enforcement of all University alcohol policies and regulations. Failure to comply with any of these policies and regulations may result in a suspension of recognized student organization status and/or student/organization charges under the East Carolina Student Code of Conduct as well as university disciplinary action.

5.3.5 At parties or events held on property within the jurisdiction of the University, violations of the policies set forth in this document may lead to the termination of the event by either a University staff person(s) and/or a Campus Police official(s) and disciplinary action against its sponsor.

5.3.6 Intoxicated/disorderly persons will be barred from entering the University's facilities or will be removed from the facilities according to Campus Police protocol.

DRAFT



**Office of the Vice Chancellor  
Health Sciences Division**

AD-48 Brody Medical Sciences Building | 600 Moye Boulevard | Mail Stop 600  
East Carolina University\* | Greenville, NC 27834-4354  
252-744-2984 office | 252-744-1612 fax

January 27, 2020

Ron Mitchelson, PhD  
East Carolina University  
Greenville, NC 27858

Dear Interim Chancellor Mitchelson:

I would appreciate your consideration of the enclosed recommendation for the initial appointment of Professor with permanent tenure for Peter Josef Jurgen Koch, PhD.

Dr. Peter J. Koch is scheduled to join East Carolina University January 31, 2020 as Chair and Professor with a recommendation for permanent tenure in the Department of Anatomy and Cell Biology, Brody School of Medicine.

Dr. Koch completed his MS in Biology at University of Heidelberg, Germany in 1987. He completed his doctoral thesis in the laboratory of Professor Dr. Werner W. Franke (German Cancer Research Center, Division of Cell Biology, Heidelberg, Germany) in 1992 and also graduated Dr.rer.nat (PhD, summa cum laude; Molecular and Cellular Biology), University of Heidelberg, Germany in 1992.

Currently he is employed at the University of Colorado Denver School of Medicine in Denver, Colorado where he is a tenured Professor in the Department of Ophthalmology. He was tenured as an Associate Professor in 2007 in the Department of Dermatology at the University of Colorado, Denver, Colorado (UC Denver) and promoted to full Professor in 2012 in the Department of Dermatology and Cell and Developmental Biology at UC Denver.

Dr. Koch's scholarly activity includes 65 manuscripts in peer-reviewed scientific journals, author of seven book chapters, and accomplished grant supporter. He is an accomplished researcher, with many active and completed projects.

For your convenience, enclosed are the following documents:

- Dr. Peter J. Koch's curriculum vitae
- ECU Personnel Action Summary Form for the Board of Trustees

If you approve, we will make arrangements for this recommendation to be placed on the agenda for the February 6<sup>th</sup> and 7<sup>th</sup> ECU Board of Trustees meeting.

Sincerely,

  
Mark Stacy, MD  
Vice Chancellor, Division of Health Sciences

Enclosures

Approve

Do Not Approve

  
Ron Mitchelson, PhD  
Interim Chancellor

1/28/2020  
Date

**EAST CAROLINA UNIVERSITY PERSONNEL ACTION SUMMARY FORM**  
*(Administrator completes Section I. and faculty member (appointee) completes Section II.)*

Section I. To be completed by the appropriate administrator(s).

Name of Appointee: Peter Josef Jurgen Koch, PhD

Department: Anatomy and Cell Biology

School/College: Brody School of Medicine

Current Rank or Title: *(if applicable)* Chair and Professor Proposed Rank or Title: Chair and Professor with Tenure

Indicate Type of Action: *(select all that apply)*

Administrative Appointment:

New Faculty Appointment:

Promotion:

Conferral of Tenure:

Other:

*(describe)*

Distinguished Professorship:

*(provide name of professorship)*

Effective Date of Action: 1/31/2020

Contract Period: Administrative Appointment: 9 mo.

12 mo.

Faculty Appointment: 9 mo.

12 mo.

Salary: \$250,000

Source(s): State Funds: \$ 250,000

\*Non-State Funds: \$ \_\_\_\_\_

*\*Indicate Sources of non-state funds generically ( i.e., grants, receipts, trust funds, endowments, medical faculty practice plan, etc.):*

Prior Recommendations/Personnel Actions:  
*(please check appropriate responses)*

Source	Recommended	Not Recommended	Not Applicable
Appropriate Unit Personnel Committee	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chair/Unit Head	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Director	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Dean	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Provost/Vice Chancellor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chancellor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Board of Trustees	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Section II. To be completed by the faculty member.

**1. Education Background:** *(indicate degree, date earned and institution, note additional study & training)*

- 1992: **Dr. rer. nat.** (Ph.D., summa cum laude; Molecular & Cellular Biology), University of Heidelberg, Germany
- 1989-1992: Doctoral thesis in the laboratory of Prof. Dr. Werner W. Franke (German Cancer Research Center, Division of Cell Biology, Heidelberg, Germany)  
Subject: "Molecular characterization of the desmosomal glycoproteins: A topologically defined cadherin subfamily"
- 1987-1988: Post-graduate student and teaching assistant at the Center for Molecular Biology in Heidelberg, Germany (Prof. Dr. Bernd Hovemann)
- 1987: **Diploma in Biology** (Masters in Biology, grade: excellent)
- 1986-1987: Diploma thesis in the laboratory of Prof. Dr. Hans C. Kaerner (German Cancer Research Center, Institute for Virology, Heidelberg, Germany)  
Subject: "Generation and selection of Herpes Simplex Virus Type-1 mutants with a deletion of the origins of replication within the S-region of the genome"
- 1982-1986: Studies in Biology at the University of Heidelberg, Germany

Scientific Training

- 1995-1998: Post-Doctoral Researcher in the laboratory of Dr. John R. Stanley (University of Pennsylvania, Department of Dermatology, Philadelphia, PA)
- 1994-1995: Guest Researcher in the laboratory of Dr. John R. Stanley (National Institutes of Health, National Cancer Institute, Dermatology Branch, Bethesda, MD)
- 1992-1994: Post-Doctoral Fellow in the laboratory of Prof. Dr. Werner W. Franke, German Cancer Research Center, Heidelberg, Germany

**2. Teaching and other professional experience:** *(Show inclusive dates, rank and/or title, institution or agency, and indicate first appointment at current institution with rank and any changes to date)*

Academic Appointments

- Since 2016: Professor, Department of Ophthalmology, UC Denver
- Since 2015: **Affiliate Faculty** Appointment, Department of Clinical Sciences, **College of Veterinary Medicine & Biomedical Sciences, Colorado State University** (teaching appointment)
- Since 2012: **Full Professor (tenured)**, Departments of Dermatology and Cell & Developmental Biology, UC Denver
- 2009-2012: Associate Professor, Department of Cell and Developmental Biology, UC Denver (secondary appointment)
- Since 2008: Graduate Faculty, Medical Scientist Training (MST) Program, UC Denver Graduate School
- 2007-2012: Associate Professor (tenured), Department of Dermatology, UC Denver
- Since 2007: Graduate Faculty, Cell Biology, Stem Cells, and Development Program (CSD), UC Denver Graduate School
- Since 2007: Graduate Faculty, Biomedical Sciences Program (BSP), UC Denver Graduate School
- Since 2007: Adjunct Assistant Professor, Department of Dermatology, Baylor College of Medicine, Houston, Texas
- 2005-2007: Member, Dan L. Duncan Cancer Center, Baylor College of Medicine, Programs in 'Cancer Biology' and 'Molecular Carcinogenesis'
- 2004-2007: Member of the faculty in Baylor College of Medicine's Graduate School of

- Biomedical Sciences (programs in 'Molecular & Cellular Biology' and 'Translational Biology and Molecular Medicine')
- 2003-2007: Assistant Professor (tenure-track) Departments of Dermatology (primary appointment) and Molecular and Cellular Biology (secondary appointment), Baylor College of Medicine
- 1998-2003: Assistant Professor (non-tenured), Departments of Molecular and Cellular Biology (primary appointment) and Dermatology (secondary appointment), Baylor College of Medicine, Houston, TX

Other UC Denver Appointments and Leadership Positions

- Since 2015 **Director**, Bioengineering Core, CU Denver ([www.medschool.ucdenver.edu/Bioengineering](http://www.medschool.ucdenver.edu/Bioengineering)); the Core designs and generates genetically engineered mice, generates induced pluripotent stem cells (iPSC); provides CRISPR/CAS-mediated genome editing in embryos and iPSC.
- Since 2008 **Chair**, Institutional Animal Care and Use Committee (IACUC), UC Denver. The committee provides oversight for all animal-related research activities at UC Denver. Dr. Koch is one of the two chairs of the IACUC. Chair responsibilities include directing the committee work (e.g. review of animal protocols, establishing policies and guidelines for the appropriate and humane use of animals in biomedical research), execution of committee policies and investigations of animal care concerns.
- 2015-2018 **Member**, CU Denver School of Medicine Promotion and Tenure Committee
- Since 2015 **Member**, Core Advisory Board, Molecular Pathology Shared Resource, CU Cancer Center
- 2013-2016: **Member**, Dean's Strategic Infrastructure for Research Committee (SIRC); UC Denver School of Medicine; this committee reviews grant applications from UC Denver faculty to support the scientific infrastructure of the school.
- 2010-2014: **Faculty Senator**, Representative of the Dermatology Department and its faculty to the Medical School Senate at UC Denver. The Senate develops and implements school-wide policies in conjunction with the Dean of Medicine.
- 2010-2015: **Director**, iPS Core at UC Denver  
The goal of this Core was to provide UC Denver investigators with the tools to utilize induced pluripotent stem (iPS) cell technology in basic, transitional and clinical research. This core function has been integrated into the Bioengineering Core (see above).
- 2007-2015: **Director**, Transgenic and Gene Targeting Core at UC Denver  
This facility provided UC Denver investigators with the ability to generate genetically engineered mouse models. Services included embryology services (e.g. pronuclear injections to generate transgenic mice; ES cell injections to generate knockout and knockin mice, embryonic rederivation and cryo-preservation; Zinc finger nuclease (ZFN)-mediated knockout approaches in mouse embryos) as well as assistance for investigators with the design of appropriate animal models for their research (consultations were provided by Dr. Koch). This Core was supported by two NIH grants as well as internal grants awarded to Dr. Koch. This core function has been replaced by the Bioengineering Core (see above).

3. Scholarly & Creative Activities:

<i>Type</i>	<i>Number</i>
Book	7
Edited Book	
Chapter	
Refereed Journal Article	65
Other Journal Article	
Juried Performance/Show	
Non-Juried Performance/Show	
Other: Editorials	1
Other: Letters to Editor	2
Other: Edited Journals	2 + ad hoc
Other: Grants	19

#### Honors/Awards

- 1999-2001: Research Career Development Award from the Dermatology Foundation, USA, 'Studies to determine the role of the desmosomal cadherin desmocollin 1 (dsc 1) in epidermal development and homeostasis.'
- 2000: Albert M. Kligman Fellowship (Travel Grant to attend the SID meeting) 1998: Travel Fellowship (Travel Grant to attend the SID meeting)
- 1997: Johnson-Beerman Award from 'The College of Physicians of Philadelphia' for 'Original Research in Dermatology'
- 1996- 1997: Research Fellowship from the Dermatology Foundation, USA
- 1994 -1995: Research Fellowship from the Karl-Thyssen Fonds, Germany (Program: Molecular and Cell Biological Analysis of Diseases)

4. Membership in professional organizations:
- The Society for Investigative Dermatology
  - International Society for Transgenic Technology

5. Professional service on campus:

New hire to ECU effective January 31, 2020

6. Professional service off campus:

#### Editorial Boards

**Associate Editor** of the journal *Cell Adhesion & Migration*  
(<http://www.landesbioscience.com/journals/celladhesion/>)

**Lead Guest Editor** for the Special Issue on "Desmosomes and Desmosomal Cadherin Function in Skin and Heart Diseases – Advancements in Basic and Clinical Research" in the journal *Dermatology Research and Practice*. (2010)

#### Ad Hoc Reviews (Scientific Journal)

Journal of Cell Biology, Journal of Cell Science, Differentiation, Developmental Biology, Proceedings of the National Academy of Science (PNAS, USA), Genes and Development, Journal of Clinical Investigation, Cell Adhesion and Migration, Molecular and Cellular Biology, Cell and Tissues Research, American Journal of Human Genetics, Nature Cell Biology, Journal of Investigative Dermatology, Experimental Dermatology, American Journal of Human Genetics, Oncogene, Nature Reviews Cancer, PLOS One, Nature Communications, Science.

Membership in Grant Review Panels

2019 ZRG1-MOSS D82 Study Section (NIH/CSR); 6/2019

2018 Reviewer for RFA "Translational Consortia for Rare Disease Research"; German Federal Ministry for Education and Research (BMBF); 7/2018

2018 Program Project Grant Review Panel for Autoimmune Diseases [site visit for the German Research Foundation (DFG), the German equivalent of the NIH)]; Lübeck, Germany; Side Visit: 3/2018

2018 ACTS Study Section (NIH/CSR); 2/2018

2017 PRCRP Melanoma and Other Skin Cancer Study Section (Department of Defense); 12/2017

2017 ZRG1 MOSS-D (82)-A Study Section (NIH/CSR); 6/2017

2017 ZRG1 F10B-B Study Section (NIH/CSR); 3/2017

2016 AMS Study Section (NIH/CSR); 11/2016

2016 ACTS Study Section (NIH/CSR); 6/2016

2015 ZAR1 KM (M1) 1; P30 Grant Applications (NIH/ NIAMS). 10/2015

2015 ZRG1 F10B-B (20) L; Fellowship Reviews, (NIH/CSR); 2015/10, 6/2015

2015 Agence Nationale de la Recherche, France, Grant Review, 6/2015

2015 DFG (German Research Foundation) Grant Review (Program Project Grant Review; Luebeck, Germany); 4/2015

2015 ZRG1 F10B-B (20) (NIH/CSR) Study Section (Fellowship Awards); 3/2015

2014 Debra International Grant Reviews (Vienna, Austria)

2014 DFG (German Research Foundation) Grant Review (Program Project Grant Review)

2014 BMFT (German Ministry of Research) Grant Review (Program Project Grant Review)

2014 CDMRP PRCRP MOSC Study Section (Department of Defense Grant Application Reviews; Melanoma and Skin Cancer Group), 11/2014

2013: CDMRP PRCRP MOSC Study Section (DOD Grant Application Reviews; Melanoma and Skin Cancer Group), 12/2013

2014: ACTS Study Section (NIAMS/NIH); 2014-1

2013: MRC (Medical Research Council, UK), Grant Review

**2013: Chair, ZRG1 MOSS QO2 Study Section (CSR/NIH); 3/2013**

2013: AMS 1 Study Section (CSR/NIH); 3/2013

2008-2012: **Permanent Member**, ACTS Study Section (NIAMS/NIH) 2011: The Myrovlytis Trust, UK (Research Grant Review)

2010: Scientific Review Group (CDMRP, Department of Defense; Skin Cancer Grant Review Group)

2009: Reviewer for CCTSI Co-Pilot Grant Applications; Colorado Clinical and Translational Sciences Institute, UC Denver

2009: Special Review Panel, Center for Scientific Review (ZRG1 MOSS-H (02); NIH)

2008: Special Review Panel, Center for Scientific Review (2009/05 ZRG1 MOSS H (02); NIH)

2006: Scientific Review Group AMS 2007-01 (NIAMS/NIH), 11/2006 2007: Scientific Review Group ACTS (NIAMS/NIH), 9/2007

2006: Scientific Review Group ZRG1 MOSS-K (6) (NIAMS/NIH), 6/2006 2006: Scientific Review Group ZRG1 MOSS-K (12) B (NIAMS/NIH), 4/2006 2006: Special Emphasis Panel / Scientific Review Group 2006/05 AMS (NIAMS/NIH), 2/2006

2006: Swiss Cancer League, Bern, Switzerland, grant Review, 9/2006 2005: Cancer Research UK, London, England, Grant Review, 12/2005

2005: Special Review Panel, Center for Scientific Review (2005/10 CSR ZRG1 MOSS K12; NIH)

2005: Special Review Panel, Center for Scientific Review (2005/05 ZRG1 MOSS-D (03); NIH)

2002, 2004: Wellcome Trust, London, England, Grant Review

2000, 2001: Special Review Panel, Center for Scientific Review, NIH 2000: Swiss National Science Foundation, Grant Review

Other Professional Activities:

- Since 2012: **Organizer** of the “Annual Retreat of the Colorado Skin Research Program” on behalf of the Department of Dermatology and the Gates Center for Regenerative Medicine
- Since 2016: **Organizer**, Annual Retreat of the Gates Center for Regenerative Medicine. 2010-2014 **Member**, Finance Committee of the Society for Investigative Dermatology

Discussion Leader at National and International Scientific Meetings

- 2019: **Co-Chair**, Minisymposia on “Growth Factors, Cell Adhesion, and Matrix Biology”, Annual Meeting of the Society for Investigative Dermatology, 2019
- 2014: **Co-Chair**, Workshop D3, Open Forum for IACUC Chairs, 2014 IACUC Conference organized by PRIMER (Public Responsibility in Medicine and Research), Denver, CO
- 2012: **Co-Chair**, Minisymposium on “Cell Adhesion and Matrix Biology”, Annual Meeting of the Society for Investigative Dermatology, 2012
- 2010: **Co-Chair**, Minisymposium on “Genetic Disease, Gene Reg. & Gene Therapy”, Annual Meeting of the Society for Investigative Dermatology, 2010
- 2009: **Co-Chair**, Minisymposium on “Genetic Disease, Gene Reg. & Gene Therapy”, Annual Meeting of the Society for Investigative Dermatology, 2009
- 2008: **Co-Chair**, Minisymposium on “Cell Adhesion/Matrix Biology”, International Meeting of the American, European and Japanese Societies for Investigative Dermatology, IID 2008
- 2005: **Co-Chair**, Minisymposium on “Genetic Disease, Gene Regulation & Gene Therapy”, Annual Meeting of the Society for Investigative Dermatology, 2005
- 2004: **Co-Chair**, Minisymposium on “Cell Adhesion/Matrix Biology”, Annual Meeting of the Society for Investigative Dermatology, 2004

Invited Lectures, Presentations at National and International Meetings

- 2019: “Molecular pathology underlying TP63-related ectodermal dysplasias”; Medical College of Georgia, Augusta University; 1/2019
- 2018: “Designing stem cell-based models to elucidate disease mechanisms underlying inherited tissue fragility disorders.” 3/2018; University of Dayton, Ohio; Center for Tissue Regeneration & Engineering
- 2017: “The molecular pathology underlying TP-63-related ectodermal dysplasias.” 9/2017; University of Iceland, Reykjavik, Iceland
- 2017: “TP63-mediated stem cell fate: From the Skin to the Eye”; 2/2017; University of Ohio, Athens, Department of Biomedical Sciences
- 2016: “TP63-mediated control of stem cell fate in ectodermal dysplasias”; 9/2016; University of Lübeck, Germany
- 2016: “NIH reviews, the reviewer’s perspective”; 5/2016; the Annual Meeting of the Society for Investigative Dermatology; SID PhD Retreat
- 2015: Colorado State University, “iPSC generation for biomedical research” 2013: Symposium on Advanced Wound Care; Annual Meeting of the Wound Healing Society, “Desmosomal adhesion in skin development, homeostasis and disease”
- 2012: Colorado State University, “Generating animal models and human stem cell-based models for basic, translational and clinical research – The Transgenic and iPS Cores at UC Denver”
- 2012: Montagna Symposium on the Biology of the Skin; Gleneden Brach, Oregon; ‘Gene Regulatory Pathways Involved in the Differential Regulation of Desmosomal Adhesion Molecules in Normal Development and Diseases.’
- 2011: Department of Dermatology, University of Pennsylvania, Philadelphia, ‘Genetically Engineered Mouse Models for Blistering Skin Diseases’.
- 2010: Infection, Immunity & Transplantation (IIT) Seminar Series in the Department of Medical Microbiology and Immunology at the University of Toledo, Ohio, ‘Desmosomal Cadherins, Autoimmune Diseases and Cancer’

- 2009: Animal Reproduction and Biotechnology Laboratory, Colorado State University, Fort Collins, 'The role of the desmosomal cadherin DSC3 in development and tissue homeostasis – from the skin to the uterus'
- 2008: International Meeting on Autoimmune Bullous Diseases, Otsu, Japan, 'Pemphigus vulgaris-like lesions in *Dsc3* null skin.'
- 2007: Department of Oral Biology, University of Nebraska Medical Center, Lincoln, Nebraska, 'The role of desmosomal proteins in skin and hair follicle homeostasis.'
- 2007: Department of Dermatology and Cutaneous Biology, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, 'Epidermal keratins and cancer – an old topic revisited.'
- 2006: Department of Dermatology, UC Denver, Aurora, CO, 'Desmosomal proteins in normal development and disease'.
- 2004: Department of Dermatology, University of Cologne, Germany, 'In vivo function of desmosomal proteins.'
- 2003: Special Lecture, Keio University School of Medicine, Tokyo, Japan, Title: 'Using a mouse model to assess *dsc1* functions in-vivo.'
- 2003: 102<sup>nd</sup> Annual Meeting of the Japanese Dermatological Association (JDA), Tokyo, Japan, Title: 'Assessment of desmocollin 1a splice variant-specific functions in the skin using genetically engineered mice.'
- 2003: International IZKF Symposium on Inflammatory Processes, University of Erlangen-Nürnberg, Germany, Title: 'Mouse models to study the function of desmosomal cadherins in the skin.'
- 2001: The 12<sup>th</sup> Japan-Korea Joint Meeting of Dermatology, Tokyo, Japan, Title: 'An inducible mouse model for epidermolysis bullosa simplex (EBS): An explanation for the absence of mosaic forms of EBS and implications for gene therapy.'
- 2001: Gordon Conference on Epithelial Differentiation and Keratinization, NH, USA, Title: 'Epithelial Differentiation'
- 2000: Annual Meeting of the Society for Investigative Dermatology (SID), in Chicago, IL, 'In Vivo Assessment of the Role of Keratin 10 End Domains in Intermediate Filament Function.'
- 1998: Joint Meeting of the European Society for Dermatological Research (ESDR), Japanese Society for Investigative Dermatology (JSID) and Society for Investigative Dermatology (SID), in Cologne, Germany, 'Pemphigus vulgaris (PV) antigen (desmoglein 3) anchors telogen hair in the follicle.'
- 1998: VIII Meeting of the European Immunodermatology Society in Rome, Italy, Title: 'Desmoglein 3 in autoimmune disease and tissue homeostasis.'
- 1997: Annual Meeting of the Society for Investigative Dermatology (SID), in Washington, D.C., 'Mice with a targeted gene disruption of pemphigus vulgaris (PV) antigen (desmoglein 3) have a phenotype similar to PV patients.'
- 1995: VIII ZMBH Forum 'Cell Biology of Disease' in Heidelberg, Germany, Title: 'Desmosomal cadherins in autoimmune disease.'
- 1995: Annual Meeting of the Society for Investigative Dermatology (SID), in Chicago, IL, 'Pemphigus vulgaris (PV) antigen (Dsg3) is localized in the lower epidermis where PV blisters occur.'
- 1993: 21st. German Cancer Conference in Hamburg, Germany, Title: 'The diagnostic potential of cadherins, a multigene family of cell adhesion molecules.'

Invited Lectures, UC Denver

- 2008: The UC Denver Cancer Center, "Keratins and Skin Cancer – An Old Topic Revisited", 6/2008
- 2012: The UC Department of Pathology Grand Rounds, "Loss of desmosome function in skin diseases and in skin cancer", 2/2012

Other Professional Oral Presentations

- 2014: Presentation to Residency Candidates (Department of Dermatology, UC- AMC),

- “Generating model systems to explore the molecular pathology underlying ectodermal dysplasias”.
- 2013: CU Boulder, “Scientific services provided by the iPSC and Transgenic Cores at UC-AMC
- 2012: Division of Pulmonary Sciences and Critical Care Medicine, “Design of animal models and human stem cell-based models for basic, translational and clinical research – The Transgenic and iPS Cores at UC Denver”, 11/2012
- 2012: IACUC (Institutional Animal Care and Use Committee) and OLAR (Office of Laboratory Animal Research) Presentation, “Genetic Engineering in Biomedical Research”, 5/2012

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---

Peter Josef Jürgen Koch, Ph.D.  
Professor (tenured)

Charles C. Gates Center for Regenerative Medicine  
Departments of Dermatology, Cell & Developmental Biology, Ophthalmology  
Director, Bioengineering Core, University of Colorado, Anschutz Medical Center

[www.medschool.ucdenver.edu/PeterKoch](http://www.medschool.ucdenver.edu/PeterKoch)

[www.medschool.ucdenver.edu/Bioengineering](http://www.medschool.ucdenver.edu/Bioengineering)

University of Colorado Denver School of Medicine

Telephone: 303-724-0051

Facsimile: 303-724-3051

E-Mail: [Peter.Koch@ucdenver.edu](mailto:Peter.Koch@ucdenver.edu)

### Education

- 1992: **Dr. rer. nat.** (Ph.D., summa cum laude; Molecular & Cellular Biology),  
University of Heidelberg, Germany
- 1989-1992: Doctoral thesis in the laboratory of Prof. Dr. Werner W. Franke (German  
Cancer Research Center, Division of Cell Biology, Heidelberg, Germany)  
Subject: "Molecular characterization of the desmosomal glycoproteins: A  
topologically defined cadherin subfamily"
- 1987-1988: Post-graduate student and teaching assistant at the Center for Molecular  
Biology in Heidelberg, Germany (Prof. Dr. Bernd Hovemann)
- 1987: **Diploma in Biology** (Masters in Biology, grade: excellent)
- 1986-1987: Diploma thesis in the laboratory of Prof. Dr. Hans C. Kaerner (German  
Cancer Research Center, Institute for Virology, Heidelberg, Germany)  
Subject: "Generation and selection of Herpes Simplex Virus Type-1  
mutants with a deletion of the origins of replication within the S-region of  
the genome"
- 1982-1986: Studies in Biology at the University of Heidelberg, Germany

### Scientific Training

- 1995-1998: Post-Doctoral Researcher in the laboratory of Dr. John R. Stanley  
(University of Pennsylvania, Department of Dermatology, Philadelphia,  
PA)
- 1994-1995: Guest Researcher in the laboratory of Dr. John R. Stanley (National  
Institutes of Health, National Cancer Institute, Dermatology Branch,  
Bethesda, MD)
- 1992-1994: Post-Doctoral Fellow in the laboratory of Prof. Dr. Werner W. Franke,  
German Cancer Research Center, Heidelberg, Germany

### Academic Appointments

- Since 2016: Professor, Department of Ophthalmology, UC Denver
- Since 2015: **Affiliate Faculty** Appointment, Department of Clinical Sciences, **College  
of Veterinary Medicine & Biomedical Sciences, Colorado State  
University** (teaching appointment)
- Since 2012: **Full Professor (tenured)**, Departments of Dermatology and Cell &  
Developmental Biology, UC Denver

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

and implements school-wide policies in conjunction with the Dean of Medicine.

2010-2015: **Director**, iPS Core at UC Denver

The goal of this Core was to provide UC Denver investigators with the tools to utilize induced pluripotent stem (iPS) cell technology in basic, transitional and clinical research. This core function has been integrated into the Bioengineering Core (see above).

2007-2015: **Director**, Transgenic and Gene Targeting Core at UC Denver

This facility provided UC Denver investigators with the ability to generate genetically engineered mouse models. Services included embryology services (e.g. pronuclear injections to generate transgenic mice; ES cell injections to generate knockout and knockin mice, embryonic rederivation and cryo-preservation; Zinc finger nuclease (ZFN)-mediated knockout approaches in mouse embryos) as well as assistance for investigators with the design of appropriate animal models for their research (consultations were provided by Dr. Koch). This Core was supported by two NIH grants as well as internal grants awarded to Dr. Koch. This core function has been replaced by the Bioengineering Core (see above).

### Honors/Awards

1999-2001: Research Career Development Award from the Dermatology Foundation, USA, 'Studies to determine the role of the desmosomal cadherin desmocollin 1 (dsc 1) in epidermal development and homeostasis.'

2000: Albert M. Kligman Fellowship (Travel Grant to attend the SID meeting)

1998: Travel Fellowship (Travel Grant to attend the SID meeting)

1997: Johnson-Beerman Award from 'The College of Physicians of Philadelphia' for 'Original Research in Dermatology'

1996- 1997: Research Fellowship from the Dermatology Foundation, USA

1994 -1995: Research Fellowship from the Karl-Thyssen Fonds, Germany (Program: Molecular and Cell Biological Analysis of Diseases)

### Professional Memberships/Organizations

The Society for Investigative Dermatology

International Society for Transgenic Technology

### Referee Work (Peer-Reviewed Journals)

Editorial Boards

**Associate Editor** of the journal *Cell Adhesion & Migration*

(<http://www.landesbioscience.com/journals/celladhesion/>)

**Lead Guest Editor** for the Special Issue on "Desmosomes and Desmosomal Cadherin Function in Skin and Heart Diseases – Advancements in Basic and Clinical Research" in the journal *Dermatology Research and Practice*. (2010)

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

- 2010: Scientific Review Group (CDMRP, Department of Defense; Skin Cancer Grant Review Group)
- 2009: Reviewer for CCTSI Co-Pilot Grant Applications; Colorado Clinical and Translational Sciences Institute, UC Denver
- 2009: Special Review Panel, Center for Scientific Review (ZRG1 MOSS-H (02); NIH)
- 2008: Special Review Panel, Center for Scientific Review (2009/05 ZRG1 MOSS H (02); NIH)
- 2006: Scientific Review Group AMS 2007-01 (NIAMS/NIH), 11/2006
- 2007: Scientific Review Group ACTS (NIAMS/NIH), 9/2007
- 2006: Scientific Review Group ZRG1 MOSS-K (6) (NIAMS/NIH), 6/2006
- 2006: Scientific Review Group ZRG1 MOSS-K (12) B (NIAMS/NIH), 4/2006
- 2006: Special Emphasis Panel / Scientific Review Group 2006/05 AMS (NIAMS/NIH), 2/2006
- 2006: Swiss Cancer League, Bern, Switzerland, grant Review, 9/2006
- 2005: Cancer Research UK, London, England, Grant Review, 12/2005
- 2005: Special Review Panel, Center for Scientific Review (2005/10 CSR ZRG1 MOSS K12; NIH)
- 2005: Special Review Panel, Center for Scientific Review (2005/05 ZRG1 MOSS-D (03); NIH)
- 2002, 2004: Wellcome Trust, London, England, Grant Review
- 2000, 2001: Special Review Panel, Center for Scientific Review, NIH
- 2000: Swiss National Science Foundation, Grant Review

### **Other Professional Activities:**

- Since 2012: **Organizer** of the “Annual Retreat of the Colorado Skin Research Program” on behalf of the Department of Dermatology and the Gates Center for Regenerative Medicine
- Since 2016: **Organizer**, Annual Retreat of the Gates Center for Regenerative Medicine.
- 2010-2014 **Member**, Finance Committee of the Society for Investigative Dermatology

### **Discussion Leader at National and International Scientific Meetings**

- 2019: **Co-Chair**, Minisymposia on “Growth Factors, Cell Adhesion, and Matrix Biology”, Annual Meeting of the Society for Investigative Dermatology, 2019
- 2014: **Co-Chair**, Workshop D3, Open Forum for IACUC Chairs, 2014 IACUC Conference organized by PRIMER (Public Responsibility in Medicine and Research), Denver, CO
- 2012: **Co-Chair**, Minisymposium on “Cell Adhesion and Matrix Biology”, Annual Meeting of the Society for Investigative Dermatology, 2012
- 2010: **Co-Chair**, Minisymposium on “Genetic Disease, Gene Reg. & Gene Therapy”, Annual Meeting of the Society for Investigative Dermatology, 2010
- 2009: **Co-Chair**, Minisymposium on “Genetic Disease, Gene Reg. & Gene Therapy”, Annual Meeting of the Society for Investigative Dermatology, 2009

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---

- 2007: Department of Oral Biology, University of Nebraska Medical Center, Lincoln, Nebraska, 'The role of desmosomal proteins in skin and hair follicle homeostasis.'
- 2007: Department of Dermatology and Cutaneous Biology, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, 'Epidermal keratins and cancer – an old topic revisited.'
- 2006: Department of Dermatology, UC Denver, Aurora, CO, 'Desmosomal proteins in normal development and disease'.
- 2004: Department of Dermatology, University of Cologne, Germany, 'In vivo function of desmosomal proteins.'
- 2003: Special Lecture, Keio University School of Medicine, Tokyo, Japan, Title: 'Using a mouse model to assess dscl functions in-vivo.'
- 2003: 102<sup>nd</sup> Annual Meeting of the Japanese Dermatological Association (JDA), Tokyo, Japan, Title: 'Assessment of desmocollin 1a splice variant-specific functions in the skin using genetically engineered mice.'
- 2003: International IZKF Symposium on Inflammatory Processes, University of Erlangen-Nürnberg, Germany, Title: 'Mouse models to study the function of desmosomal cadherins in the skin.'
- 2001: The 12<sup>th</sup> Japan-Korea Joint Meeting of Dermatology, Tokyo, Japan, Title: 'An inducible mouse model for epidermolysis bullosa simplex (EBS): An explanation for the absence of mosaic forms of EBS and implications for gene therapy.'
- 2001: Gordon Conference on Epithelial Differentiation and Keratinization, NH, USA, Title: 'Epithelial Differentiation'
- 2000: Annual Meeting of the Society for Investigative Dermatology (SID), in Chicago, IL, 'In Vivo Assessment of the Role of Keratin 10 End Domains in Intermediate Filament Function.'
- 1998: Joint Meeting of the European Society for Dermatological Research (ESDR), Japanese Society for Investigative Dermatology (JSID) and Society for Investigative Dermatology (SID), in Cologne, Germany, 'Pemphigus vulgaris (PV) antigen (desmoglein 3) anchors telogen hair in the follicle.'
- 1998: VIII Meeting of the European Immunodermatology Society in Rome, Italy, Title: 'Desmoglein 3 in autoimmune disease and tissue homeostasis.'
- 1997: Annual Meeting of the Society for Investigative Dermatology (SID), in Washington, D.C., 'Mice with a targeted gene disruption of pemphigus vulgaris (PV) antigen (desmoglein 3) have a phenotype similar to PV patients.'
- 1995: VIII ZMBH Forum 'Cell Biology of Disease' in Heidelberg, Germany, Title: 'Desmosomal cadherins in autoimmune disease.'
- 1995: Annual Meeting of the Society for Investigative Dermatology (SID), in Chicago, IL, 'Pemphigus vulgaris (PV) antigen (Dsg3) is localized in the lower epidermis where PV blisters occur.'
- 1993: 21st. German Cancer Conference in Hamburg, Germany, Title: 'The diagnostic potential of cadherins, a multigene family of cell adhesion molecules.'

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---

- Course Director**, CSDV7670; Stem Cells and Stem Cell Technology in Biomedical, Research (course director, together with Maranke Koster; one credit class), 2/2016
- Lecturer, IDPT 7646; “Disease modeling using genetically engineered animals and induced pluripotent stem cells”, 9/2015
- Lecturer, IDPT 7821; Biomedical Sciences Core Course, Integrating Cells into Tissues: Cell-Cell and Cell-Matrix Adhesion, ECM, 10/2015
- Lecturer, IDPT 7808; Biomedical Sciences Core Course: “Transgenic Models”; 11/2015
- Lecturer, IDPT7646; Tissue Biology and Disease Mechanisms: Developing Disease Models and New Treatments for Skin Disorders”; 9/2015
- Lecturer, BIOE; Introduction to Laboratory Animal Research, Basic Principles of Genetic Engineering of Animals and Stem Cells; 3/5/2015
- Lecturer, IDPT 7808; Biomedical Sciences Core Course, “Transgenic Models”; 11/2014
- Lecturer, IDPT 7821; Biomedical Sciences Core Course, Integrating Cells into Tissues: Cell-Cell and Cell-Matrix Adhesion, ECM, 10/2014
- Lecturer, TD7646; “Novel Approaches to Study Skin Diseases”; 9/2014
- Lecturer, GSDR (Global Skin Research Consortium, UC SOM; Didactic lectures for graduate students and postdocs from 3 continents; “Mouse-Based Disease Modeling”, 7/28/2014; “iPS Cells: Basics and Stem Cell-Based Disease Models”; 7/29/2014
- Lecturer, BIOE; Introduction to Laboratory Animal Research, Basic Principles of Genetic Engineering of Animals and Stem Cells; 3/5/2014
- Lecturer, IDPT7824; Biomedical Sciences Core Course; 12/2/2013; “Transgenic Technology and Genome Editing Approaches”
- Lecturer, IDPT7824; Biomedical Sciences Core Course; 10/2/2013; “Integrating Cells into Tissues, Cell-Cell and Cell-Matrix Adhesion, Extracellular Matrix, Adhesive Interactions.
- Lecturer, BIOE 5420, “Transgenic and Stem Cell Technology”; 3/2013
- Lecturer, IDPT7813; Biomedical Sciences Core Course; 11/2, 11/5-11/6/2012; Integrating Cells into Tissues, Cell-Cell and Cell-Matrix Adhesion, Transgenic Technology, iPS and Stem Cell Approaches in Biomedical Research
- Lecturer, CSDV 7605 Stem Cells and Development: An Integrated Approach, “Induced Pluripotent Stem Cells”, 4/2012
- Lecturer, CANB7660, Extracellular Matrix Molecules in Skin Development, Wound Healing and Skin Cancer; 3/29/2012 (Lecture and Journal Club; Course Director, Dr. Pepper Schedin; Cancer Biology Graduate Program; Course: “Tissue-based theory of carcinogenesis & the microenvironment”)
- Lecturer, Transgenic Technology in Biomedical Research and Regenerative Technology, Introduction to Laboratory Animal Research (Course Director, Dr. Lujan), 2/2012
- Lecturer, IDPT7813; Biomedical Sciences Core Course; 11/4, 11/4, 11/8/2011;

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

- Lyndah Chow, PhD student, Department of Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Colorado State University (PhD committee member), 2015-2018

### Mentored Fellows

Susan Mathai, MD, Fellow Division of Pulmonary Sciences & Critical Care Medicine; I am a member of Dr. Mathai's research advisory committee; since 2014.

### Research Fellow Training:

Jiangli Chen, DVM, Ph.D., 2004-2010 (JC is now a junior faculty member in my team)

Etienne Tokonzaba, Ph.D., 2008-2013

Nityanand Maddodi, PhD, 2014-2016

### Mentored Junior Faculty:

Jiangli Chen, DVM, PhD, Instructor, since 2010

Radhika Ganeshan, PhD, Instructor, 2009-2012

### Community Outreach & Education:

3/2018 Research Day, Program for Denver high school students organized by the Department for Cell & Developmental Biology; Presentation: "Stem Cell Applications in Regenerative Medicine and Biomedical Research"

3/2017 Research Day, Program for Denver high school students organized by the Department for Cell & Developmental Biology; Presentation: "Growing human and animal stem cells in the laboratory"

7/2015 Stem Cell Laboratory Tour and Science Fair for participants of the Annual Conference of the National Foundation of Ectodermal Diseases (organized together with Maranke Koster, Dermatology)

9/2014: Presentation to High School Students: "Novel Trends in Biomedical Research – Modeling Skin Diseases"

10/2012: Presentation to High School Students: "Animal Models and Stem Cells in Biomedical Research"

7/2012: Presentation to High School Students: "Genetic Engineering in Biomedical Research"

### Baylor College of Medicine, Houston, TX (until 2007)

Graduate Faculty Appointments ("Graduate School of Biomedical Sciences, Baylor College of Medicine") in the following programs:

Molecular & Cellular Biology

Translational Biology and Molecular Medicine

Member of the "Standing Examination Committee" of the Graduate Program in Molecular & Cellular Biology, Graduate School of Biomedical Sciences, 2005-2008. This committee conducts qualifying examinations that are required for admission to Ph.D. candidacy.

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---

Title: Mechanisms underlying tissue fragility in ectodermal dysplasias  
 Funding Agency: NIH/NIAMS  
 Investigator Relationship: PI (Multi PI application, Co-PI: Maranke Koster)  
 Dates of Funding: 09/21/2017 – 07/31/2022  
 Type: R01AR072621; Grant

---

Title: Limbal stem cell deficiency in EEC  
 Funding Agency: National Foundation for Ectodermal Dysplasias  
 Investigator Relationship: PI (Multi PI application, Co-PI: Maranke Koster)  
 Dates of Funding: 10/01/2017 – 01/30/2020  
 Type: Research Grant

---

Title: Molecular Analysis, Modeling and Correction of Skin Diseases  
 Funding Agency: NIH/NIAMS  
 Investigator Relationship: Core Director, Bioengineering Core (PI, David Norris)  
 Dates of Funding: 8/20/2014- 9/28/2019  
 Type: 2P30AR057212-06; Grant

---

### **Institutional Grants (UC Denver):**

(PI, Koch, Peter J.) 10/01/2007-

University of Colorado Denver \$203,073

*Academic Enrichment Funds*

To provide support for the *Transgenic and Gene Targeting Core* at University of Colorado Denver (now the Bioengineering Core)

---

(PI, Koch, Peter J.) 01/01/2011-

University of Colorado Denver \$750,000

*Academic Enrichment Funds*

To provide support for the Induced Pluripotent Stem Cell (iPS) Core at University of Colorado Denver (now the Bioengineering Core)

### **Completed**

Title: Colorado Clinical and Translational Sciences Institute  
 CTSA Application (CCTSI);  
 Funding Agency: NIH/NCRR  
 Investigator Relationship: Core Director (CCTSI Translational Therapeutics and  
 Modeling Core) (PI, Sokol, Ronald J)  
 Dates of Funding: 10/1/2013- 4/30/2018  
 Type: 2P30AR057212-06; Grant

---

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---

Dates of Funding: 4/1/2011-12/1/2012  
 Type: Grant (R21)

---

Title: Towards a cure for skin erosions in AEC patients  
 Funding Agency: National Foundation for Ectodermal Dysplasias  
 Investigator Relationship: Co-PI (multi PI proposal, together with Maranke Koster, Department of Dermatology)

Dates of Funding: 4/1/2011-3/31/2012  
 Type: Grant

---

Title: The Role of Desmocollin 3 in the Development and Maintenance of Epithelial Tissues (RO1 AR050439)

Funding Agency: NIH/NIAMS

Investigator Relationship: PI

Dates of Funding: 07/12/2004 - 03/31/2009 (on no-cost extension until 3/31/2011)

Type: Grant (RO1)

---

Title: Desmocollin 1 in Epidermal Development & Homeostasis (5 R01 AR47343)

Funding Agency: NIH/NIAMS

Dates of Funding: 03/01/2001 - 02/28/2006 (currently on a no-cost extension until 2/28/2007)

Type: Grant

---

Title: Molecular Mechanisms of Skin and Appendage Development (P01 AR47898)

Funding Agency: NIH/NIAMS

Investigator Relationship: Director, ES Cell Core

Dates of Funding: 09/01/2001 - 08/31/2008

Type: Grant

---

Title: Studies to Determine the Role of the Desmosomal Cadherin Desmocollin 1 (dsc1) in Epidermal Development and Homeostasis

Funding Agency: Dermatology Foundation

Investigator Relationship: PI

Dates of Funding: 1999-2002

Type: Research Career Development Award

---

Title: Studies to Determine the Role of the Desmosomal Cadherin Desmocollin 1 (dsc1) in Epidermal Development and Homeostasis

Funding Agency: Foundation for Ichthyosis and Related Skin Types / Dermatology Foundation

Investigator Relationship: PI

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---

### Bibliography & Contributions to Science:

1. My early work focused on the molecular characterization of desmosomal adhesion proteins. This work identified these proteins as a subfamily of cadherins and enabled me and others to design experiments to characterize the roles of these protein in development. During my postdoctoral training at the NIH and later at the University of Pennsylvania (PI: John Stanley), I generated knockout lines for a key desmosomal protein, desmoglein 3 (Dsg3). These experiments demonstrated that ablation of the Dsg3 gene leads to a phenotype which mimics pemphigus vulgaris, an autoimmune disease in which patients develop DSG3 autoantibodies. These studies significantly advanced our understanding of the role of desmosomal proteins in normal development and diseases.

Mahoney, M.G., Z.Wang, K.Rothenberger, P.J.Koch, M.Amagai, and J.R.Stanley. 1999. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. *J. Clin. Invest.*103:461-468. PMID:PMC408100

Koch, P.J., M.G.Mahoney, G.Cotsarelis, K.Rothenberger, R.M.Lavker, and J.R.Stanley. 1998. Desmoglein 3 anchors telogen hair in the follicle. *J. Cell Sci.* 111 (Pt 17):2529-2537. PMID:9701552

Koch, P.J., M.G.Mahoney, H.Ishikawa, L.Pulkkinen, J.Uitto, L.Shultz, G.F.Murphy, D.Whitaker-Menezes, and J.R.Stanley. 1997. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. *J. Cell Biol.* 137:1091-1102. PMID:PMC2136216

2. Once I established my own NIH-funded laboratory, I continued to work on the role of desmosomal cadherins in normal development and diseases. We demonstrated, for example, that loss of desmocollin 3 (DSC3) in the skin induced a skin fragility phenotype similar to pemphigus vulgaris (see above). At that time, DSC3 had not been linked to human disorders. Our mouse model predicted the existence of a new type of human disease. Subsequently, several groups provided evidence in support of this hypothesis. We also demonstrated that loss of desmosomal gene expression can play an important role during cancer development and progression.

Chen, J., Z. Den, and Peter J. Koch. 2008. Loss of desmocollin 3 in mice leads to epidermal blistering. *J Cell Sci.* 121:2844-2849 PMID:PMC2659849

Chen, J., C. O'Shea, J.E. Fitzpatrick, M.I. Koster, and Peter J. Koch 2011. Loss of desmocollin 3 in skin tumor development and progression. *Molecular Carcinogenesis, Mol Carcinogen.* PMID:PMC3178010

Ganeshan, R., J. Chen, and Peter J. Koch 2010. Mouse models for blistering skin disorders. *Dermatology Research and Practice*, Article ID 584353 (online format)

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---

Koch, P.J., Dinella, J., Fete, M., Siegfried, E.C., and Koster, M. I. Modeling AEC – New approaches to study rare genetic disorders. *Am J Med Genet A*, Mar 24. doi: 10.1002/ajmg.a.36455. [Epub ahead of print], 2014. PMID: PMC4526214

Koster, M.I., Dinella, J. Chen, J., O’Shea, C., and Peter J Koch. 2014. Integrating animal models and in vitro models to elucidate the role of desmosomal proteins in diseases. *Cell Commun Adhes.* 21:55-63 PMID: PMC4117210

Dinella, J.D., Chen, J., Webb, S., Siegfried, E., Bree, A.F., Lakshmanachetty, S., Balaiya, V., Koster, M.I., and Peter J Koch. A Human Stem Cell-Based System to Study the Role of TP63 Mutations in Ectodermal Dysplasias. *Journal Investigative Dermatology.* 138:1662-1665, 2018 PMID: 29481901 PMID: PMC6019602

### Complete Bibliography at:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1jmEDZkJMj-AB/bibliography/43676111/public/?sort=date&direction=ascending>.

### Bibliography

1. Ostermann A, Wunderlich C, Schneiders L, Vogt M, Woeste M, Belgardt B, Nissan C, Martiny B, Schauss A, Frommolt P, Nikolaev A, Hövelmeyer N, Sears R, **Koch PJ**, Günzel D, Brüning J, Wunderlich T. Intestinal insulin/IGF1 signaling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer; *Nature Metabolism; in press*
2. Choi YJ, Laclef C, Yang N, Cervera AA, Lewis J, Mao X, Li L, Snedecor ER, Takemaru KI, Qin C, Schneider-Maunoury S, Shroyer KR, Hannun YA, **Koch PJ**, Clark RA, Payne AS, Kowalczyk AP, Chen J. RPGRIP1L is required for stabilizing epidermal keratinocyte adhesion through regulating desmoglein endocytosis; *PLOS Genetics; in press*
3. Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O’Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, **Koch PJ**, O’Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. Altered cell-cycle control, inflammation and adhesion in high-risk persistent bronchial dysplasia. *Cancer Res.* 2018 Jul 11. pii: canres.3822.2017. doi: 10.1158/0008-5472.CAN-17-3822. [Epub ahead of print]
4. Dinella, JD, Chen, J, Webb, S, Siegfried, E, Bree AF, Lakshmanachetty, S., Balaiya, V. Koster, MI, and **Koch PJ**. A human stem cell-based system to study the role of TP63 mutations in ectodermal dysplasias. *Journal Investigative Dermatology.* 138:1662-1665
5. Chow, L, Johnson, V, Regan, D, W, Webb, S, **Koch, PJ**, and Dow S. Safety and immunogenicity of canine induced pluripotent stem cell derived mesenchymal stem cells, *Stem Cell Research, Stem Cell Res*, 2017, **25**, 221-232

---



---

**CURRICULUM VITAE – Peter J. Koch, Ph.D.**


---



---

20. Chen, J., K. Jaeger, Z. Den, **Peter J. Koch**, John P. Sundberg, and Dennis R. Roop. 2008. Mice expressing a mutant Krt75 (K6hf) allele develop hair and nail defects resembling pachyonychia congenita. *J. Invest. Dermatol.* 128:270-279
21. Schmidt, A. and **P. J. Koch**. 2007. Desmosomes: Just Cell Adhesion or is there more? *Cell Adhesion & Migration*. 1:28-32.
22. Chen, J., X. Cheng, M. Merched-Sauvage, Dennis R. Roop, and **P. J.Koch**. 2006. An unexpected role for keratin 10 end domains in susceptibility to skin cancer. *J. Cell Sci*. 119: 5067-5076
23. Den, Z., X.Cheng, M.Merched-Sauvage, and **P.J.Koch**. 2006. Desmocollin 3 is required for pre-implantation development of the mouse embryo. *J. Cell Sci*. 119:482-489.
24. Cheng, X., Z.Den, and **P.J.Koch**. 2005. Desmosomal cell adhesion in mammalian development. *Eur. J. Cell Biol*. 84:215-223.
25. Yang, T., D.Liang, **P.J.Koch**, D.Hohl, F.Kheradmand, and P.A.Overbeek. 2004. Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosin in Spink5<sup>-/-</sup> mice. *Genes Dev*. 18:2354-2358.
26. Cheng, X., K.Mihindukulasuriya, Z.Den, A.P.Kowalczyk, C.C.Calkins, A.Ishiko, A.Shimizu, and **P.J.Koch**. 2004. Assessment of splice variant-specific functions of desmocollin 1 in the skin. *Mol. Cell Biol*. 24:154-163.
27. Cheng, X. and **P.J.Koch**. 2004. In vivo function of desmosomes. *J. Dermatol*. 31:171-187.
28. **Koch,P.J.**, T.Cao, M.Arin, and D.R.Roop. An inducible mouse model for epidermolysis bullosa simplex (EBS): An explanation for the absence of mosaic forms of EBS and implications for gene therapy. 67-76. 2002. *The 12th Japan-Korea Joint Meeting of Dermatology*. 11-8-2001.
29. Suga, Y., M.Jarnik, P.S.Attar, M.A.Longley, D.Bundman, A.C.Steven, **P.J.Koch**, and D.R.Roop. 2000. Transgenic mice expressing a mutant form of loricrin reveal the molecular basis of the skin diseases, Vohwinkel syndrome and progressive symmetric erythrokeratoderma. *J Cell Biol* 151:401-412.
30. Lenox, J.M., **P.J.Koch**, M.G.Mahoney, M.Lieberman, J.R.Stanley, and G.L.Radice. 2000. Postnatal lethality of P-cadherin/desmoglein 3 double knockout mice: demonstration of a cooperative effect of these cell adhesion molecules in tissue homeostasis of stratified squamous epithelia. *J. Invest.Dermatol*. 114:948-952.
31. **Koch, P.J.**, P.A.de Viragh, E.Scharer, D.Bundman, M.A.Longley, J.Bickenbach, Y.Kawachi, Y.Suga, Z.Zhou, M.Huber, D.Hohl, T.Kartasova, M.Jarnik, A.C.Steven, and D.R.Roop. 2000. Lessons from loricrin-deficient mice. Compensatory mechanisms maintaining skin barrier function in the absence of a major cornified envelope protein. *J Cell Biol* 151:389-400.
32. Mahoney, M.G., Z.Wang, K.Rothenberger, **P.J.Koch**, M.Amagai, and J.R.Stanley. 1999. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. *J. Clin. Invest*.103:461-468.
33. **Koch, P.J.**, M.G.Mahoney, G.Cotsarelis, K.Rothenberger, R.M.Lavker, and J.R.Stanley. 1998. Desmoglein 3 anchors telogen hair in the follicle. *J. Cell Sci*. 111 ( Pt 17):2529-2537.
34. **Koch, P.J.**, M.G.Mahoney, H.Ishikawa, L.Pulkkinen, J.Uitto, L.Shultz, G.F.Murphy, D.Whitaker-Menezes, and J.R.Stanley. 1997. Targeted disruption of the pemphigus

---



---

## CURRICULUM VITAE – Peter J. Koch, Ph.D.

---



---

49. **Koch, P.J.**, M.D.Goldschmidt, M.J.Walsh, R.Zimbelmann, M.Schmelz, and W.W.Franke. 1991. Amino acid sequence of bovine muzzle epithelial desmocollin derived from cloned cDNA: a novel subtype of desmosomal cadherins. *Differentiation* 47:29-36.
50. **Koch, P.J.**, M.D.Goldschmidt, M.J.Walsh, R.Zimbelmann, and W.W.Franke. 1991. Complete amino acid sequence of the epidermal desmoglein precursor polypeptide and identification of a second type of desmoglein gene. *Eur. J. Cell Biol.* 55:200-208.
51. **Koch, P.J.**, M.J.Walsh, M.Schmelz, M.D.Goldschmidt, R.Zimbelmann, and W.W.Franke. 1990. Identification of desmoglein, a constitutive desmosomal glycoprotein, as a member of the cadherin family of cell adhesion molecules. *Eur. J. Cell Biol.* 53:1-12.

### Books and Book Chapters

1. Arin, M.J., Roop, D.R., **Koch, P.J.**, and M. I. Koster. Biology of Keratinocytes. In *Dermatology 4<sup>th</sup> edition*, J. Bologna editor. Elsevier, 2017
2. Arin, M.J., Roop, D.R., **Koch, P.J.**, and M. I. Koster. Biology of Keratinocytes. In *Dermatology 3<sup>rd</sup> edition*, J. Bologna editor. Elsevier, in press
3. Schmidt, A., and **P.J. Koch**. 2008. Desmosomes in Development and Diseases. In: *Cell Junctions: Adhesion, Development and Disease*, A. Kowalczyk and S. LaFlamme editors, Wiley-VCH, Weinheim, Germany
4. Arin, M.J., Roop, D.R., **Koch, P.J.**, and M. I. Koster. Biology of Keratinocytes. In *Dermatology 2<sup>nd</sup> edition*, J. Bologna editor. Elsevier, 2007
5. **Koch, P.J.**, Z.Zhou, and D.R.Roop. 2004. Cornified Envelope and Corneocyte-Lipid Envelope. In *Skin Barrier*. P.M.Elias and K.R.Feingold, editors. Marcel Dekker, Inc., New York.
6. **Koch, P.J.** and D.R.Roop. 2002. Loricrin. In *Wiley Encyclopedia of Molecular Medicine*. John Wiley & Sons Inc., New York. 1956-1959.
7. Kartenbeck, J., **P.J.Koch**, and W.W.Franke. 1993. Desmoglein. In *Guidebook to the Extracellular Matrix and Adhesion Proteins*. T.Kreis and R.Vale, editors. Oxford University Press, Oxford, New York, Tokyo. 133-135.

### Letters to the Editor

8. Chen, J., X. Cheng, M. Merched-Sauvage, Dennis R. Roop, and **P. J.Koch**. 2007. Response to "The ends of a conundrum?", *J. Cell Sci.*, 120:1147-1148
9. **Koch, P.J.** and D.R.Roop. 2004. The role of keratins in epidermal development and homeostasis-going beyond the obvious. *J. Invest.Dermatol.* 123:x-xi.

### Editorials

10. My G. Mahoney, Eliane Mueller, and **Peter J. Koch**. Desmosomes and Desmosomal Cadherin Function in Skin and Heart Diseases—Advancements in Basic and Clinical Research. *Dermatology Research and Practice*, Article ID 725647 (online format), 2010\_ <http://www.hindawi.com/journals/drp/2010/725647.html>



January 27, 2020

Ron Mitchelson, PhD  
East Carolina University  
Greenville, NC 27858

Dear Interim Chancellor Mitchelson:

I would appreciate your consideration of the enclosed recommendation for the initial appointment of Professor with permanent tenure for Maranke Koster, PhD.

Dr. Maranke Koster is scheduled to join East Carolina University February 28, 2020 as Professor with a recommendation for permanent tenure in the Department of Anatomy and Cell Biology, Brody School of Medicine.

Dr. Koster completed her MS in Medical Biology at VU University, Amsterdam, The Netherlands in 1999, while also completing a Pre-Master Fellowship simultaneously at the Laboratory of Dr. W.N. Hittelman, University of Texas M.D. Anderson, Cancer Center in Houston, Texas. She completed her PhD in Developmental Biology, Laboratory of Dr. D.R. Roop, at Baylor College of Medicine in Houston, Texas in 2004 and also completed a postdoctoral fellowship there in 2007.

Currently she is employed at the University of Colorado School of Medicine in Aurora, Colorado where she is an Associate Professor in the Department of Ophthalmology (2016 to current); Associate Professor in the Department of Dermatology (2013 to current) and Director in the Department of Morphology and Phenotyping Core.

Dr. Koster's scholarly activity includes 50 manuscripts in peer-reviewed scientific journals, author of six book chapters, and accomplished grant supporter. She is a gifted researcher, with many active and completed projects.

For your convenience, attached are the following documents:

- Dr. Maranke Koster's curriculum vitae
- ECU Personnel Action Summary Form for the Board of Trustees

If you approve, we will make arrangements for this recommendation to be placed on the agenda for the February 6<sup>th</sup> and 7<sup>th</sup> ECU Board of Trustees meeting.

Sincerely,

Mark Stacy, MD  
Vice Chancellor, Division of Health Sciences

Enclosures

Approve

Do Not Approve

\_\_\_\_\_  
Ron Mitchelson, PhD  
Interim Chancellor

\_\_\_\_\_  
Date

**CURRICULUM VITAE**  
**Maranke I. Koster, Ph.D.**

Present Address: Department of Dermatology  
University of Colorado - Anschutz Medical Campus  
Building RC-1 North, Room P18-8131  
12800 East 19<sup>th</sup> Avenue  
Mail Stop 8320  
Aurora, CO 80045  
Phone: (303) 724-1640  
Fax: (303) 724-3051  
E-mail: Maranke.Koster@cuanschutz.edu

**Personal Statement**

I have been a faculty member at the University of Colorado Medical School since 2007 and was appointed to the rank of Associate Professor in 2013. I am currently affiliated with the Departments of Dermatology and Ophthalmology, as well as with the Gates Center for Regenerative Medicine and the University of Colorado Cancer Center. I have been an independent principal investigator with continued NIH grant support since 2007 (e.g. K99/R00 and R01 mechanisms). In addition, I have had continuous support for my research from private foundations. I have published 50 manuscripts in peer-reviewed scientific journals and am an author or senior author of 6 book chapters. I have been appointed to leadership positions in national and international scientific societies (e.g. Board of Directors, Society for Investigative Dermatology; Scientific Advisory Council, National Foundation for Ectodermal Dysplasias). Further, I regularly review grant applications for the NIH, and other national and international funding agencies. I am also a former member of the editorial boards of two peer-reviewed scientific journals (Experimental Dermatology; PLOS One). I have a track record of leadership functions in the graduate school, both in administration (e.g. admission committee) and in the development of graduate classes in the areas of regenerative medicine, stem cell biology, and developmental biology. Finally, I have directed a histology core facility since 2008.

Research in my laboratory is aimed at investigating the role of the transcription factor TP63 in the development and maintenance of the skin and cornea. Mutations in TP63 underlie a set of inherited disorders (ectodermal dysplasias) that are characterized by extreme skin and cornea fragility. In collaboration with the Koch laboratory we are developing in vitro and in vivo models to identify the pathological mechanisms underlying tissue fragility in these patients. Finally, my laboratory also investigates the role of TP63 in the development and progression of human skin and head & neck squamous cell carcinomas.

**EDUCATION/TRAINING**

1994-1999	M.S., Medical Biology, VU University, Amsterdam, The Netherlands
1998-1999	Pre-Master Fellow, Laboratory of Dr. W.N. Hittelman, University of Texas M.D. Anderson Cancer Center, Houston, TX
1999-2004	Ph.D., Program in Developmental Biology, Laboratory of Dr. D.R. Roop, Baylor College of Medicine, Houston, TX
2004-2007	Postdoctoral Fellow, Department of Molecular and Cellular Biology, Laboratory of Dr. D.R. Roop, Baylor College of Medicine, Houston, TX

**APPOINTMENTS**

- 2007-2013 Assistant Professor, Department of Dermatology, University of Colorado School of Medicine, Aurora, CO
- 2008-current Director, Morphology and Phenotyping Core, University of Colorado School of Medicine, Aurora, CO
- 2013-current Associate Professor, Department of Dermatology, University of Colorado School of Medicine, Aurora, CO
- 2016-current Associate Professor, Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO

**OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS**

- 2007-current Member, Gates Center for Regenerative Medicine, University of Colorado School of Medicine, Aurora, CO
- 2007-current Member, Cell Biology, Stem Cells and Development (CSD) Graduate Program, University of Colorado School of Medicine, Aurora, CO
- 2008-current Member, Biomedical Sciences Graduate Program (BSP), University of Colorado School of Medicine, Aurora, CO
- 2008-current Member, Scientific Advisory Council, National Foundation for Ectodermal Dysplasias (NFED), Fairview Heights, IL
- 2009-current Member, University of Colorado Cancer Center (UCCC), Aurora, CO
- 2009-current Member, Colorado Clinical and Translational Sciences Institute (CCTSI)
- 2010-current Member, Intellectual and Developmental Disabilities Research Center (IDDRC), University of Colorado School of Medicine, Aurora, CO

**AWARDS**

- 2003 IID2003 Travel Fellowship Award to attend the International Investigative Dermatology Meeting
- 2003 First place poster award, Gordon Research Conference on Epithelial Differentiation & Keratinization
- 2004 First place abstract basic science, 2<sup>nd</sup> Annual Cancer Center Symposium, Baylor College of Medicine Cancer Center
- 2005 Society for Investigative Dermatology Eugene M. Farber Endowment Travel Award, William Montagna Symposium on the Biology of the Skin
- 2006 Albert M. Kligman Travel Fellowship, Society for Investigative Dermatology
- 2008 IID2008 Travel Fellowship Award to attend the International Investigative Dermatology Meeting
- 2011 JSID/SID Young Investigator Collegiality Award to support travel to the 2011 Annual Meeting of the Japanese Society of Investigative Dermatology

**PROFESSIONAL ASSOCIATIONS**

- 2006-current The Society for Investigative Dermatology
- 2009-current National Foundation for Ectodermal Dysplasias
- 2012-current North American Hair Research Society

**COMMITTEE AND SERVICE RESPONSIBILITIES**

***University***

- 2007-2009 Member, Admissions Committee, CSD Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO
- 2009 Co-Chair, Annual Retreat of the CSD Graduate Program, Vail, CO, October 2-3, 2009
- 2010-2013 Member, Executive Committee, CSD Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO
- 2010 Chair, Annual Retreat of the CSD Graduate Program, Estes Park, CO, October 1-2, 2010
- 2010 Chair, Admissions Committee, CSD Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO
- 2011-2018 Member, Admissions Committee, BSP Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO
- 2012-2015 Co-Chair, Annual Retreat of the Colorado Skin Research Program, Estes Park, CO, September 7-8, 2012 and June 28-29, 2013

***National***

- 2009 Co-chair, Concurrent minisymposium “Hair and Cutaneous Development”, Annual meeting of the Society for Investigative Dermatology (SID), Montreal, Canada, May 9, 2009
- 2010 Co-chair, Concurrent minisymposium “Hair and Cutaneous Development I: Embryonic Skin Development/Stem Cell Functions”, Annual meeting of the Society for Investigative Dermatology (SID), Atlanta, Georgia, May 7, 2010
- 2011 Member, Organizing committee for the first annual PhD retreat held prior to the 2012 meeting of the Society for Investigative Dermatology (SID)
- 2012-current Member, Ectodermal Dysplasia Classification Committee
- 2013-2018 Member, Board of Directors of the Society for Investigative Dermatology (SID)

***International***

- 2013-current University of Colorado Coordinator, Global Skin Disease Research Consortium (GSDRC)

**REVIEW AND REFEREE WORK**

***Grant review committees and study sections***

- 2009-current Research Grants Council (RGC) of Hong Kong
- 2009-current National Foundation for Ectodermal Dysplasias (NFED)
- 2009, 2010 Netherlands Organisation for Scientific Research (NWO; The Netherlands)
- 2010-current Telethon Foundation (Italy)
- 2010 Medical Research Council (UK)
- 2011 Wellcome Trust (UK)
- 2011 NIH; Special Emphasis Panel/Scientific Review Group 2011/05 ZRG1 EMNR-C (02) M
- 2011 The National Science Foundation (NSF)
- 2012, 2013 NYSTEM (New York State Stem Cell Science), Stem Cell Differentiation and Lineage panel
- 2012 Deutsche Forschungsgemeinschaft (DFG; Germany)
- 2013 NIH; 2013/05 ACTS (Arthritis, Connective Tissue and Skin Study Section)
- 2013 NIH; Special Emphasis Panel: Dermatology, Rheumatology and Inflammation; ZRG1 MOSS T(03)
- 2013 NIH; Small Business Panel: Dermatology, Rheumatology and Inflammation; ZRG1 MOSS T(12)
- 2014 Action Medical Research (UK)

2014 Biotechnology and Biological Sciences Research Council (UK)  
2014 Maïmonide-Israel Research Program (Israel-France)  
2015 NIH; 2016/01 ACTS (Arthritis, Connective Tissue and Skin Study Section)  
2016 NIH; 2016/02 ACTS (Arthritis, Connective Tissue and Skin Study Section)  
2016 National Science Center (Poland)  
2016 Research Councils UK  
2016 NYSTEM (New York State Stem Cell Science), Musculoskeletal and Skin panel  
2017 NIH; ZRG1 MOSS-C(12) (Dermatology, Rheumatology and Inflammation)  
2017 DEBRA International  
2018 NSF; Graduate Research Fellowships (GRFP) – Cell Biology Panel  
2018 NIH; Special Emphasis Panel 2018/05 ZRG1 F10B-B (20)  
2018 NIH; Special Emphasis Panel 2018/10 ZRG1 F10B-B (20) L  
2018 Center for the Advancement of Science in Space (CASIS)  
2018 British Skin Foundation (UK)  
2018, 2019 NSF; Graduate Research Fellowships (GRFP) – Cell Biology Panel  
2018 NIH; Special Emphasis Panel 2018/05 ZRG1 F10B-B (20)  
2019 VINMEC healthcare system Vietnam  
2019 NIH; Special Emphasis Panel 2019/05 ZRG1 F05-U (20) M  
2019 NIH; Special Emphasis Panel 2019/10 ZRG1 F05-U (20) M  
2019 NIH; Small Business Panel 2020/01 ZRG1 MOSS-C (12) B

***Editorial board memberships***

2013-2018 Member, Editorial Board of Experimental Dermatology  
2014-2017 Member, Editorial Board of PLOS One

***Ad hoc reviewer for journals***

Journal of Investigative Dermatology, Journal of the European Academy of Dermatology and Venereology, Stem Cells, Dermatology Research and Practice, PLoSOne, Journal of Biological Chemistry, Molecular Biology of the Cell, Experimental Dermatology, Journal of Biomedicine and Biotechnology, American Journal of Medical Genetics, Apoptosis, Proceedings of the National Academy of Science USA, Journal of Cell Biology, Biochemical Pharmacology, Journal of Medical Case Reports, Cell Death and Differentiation, Journal of Clinical Investigation, Cell Death and Disease, Molecular Carcinogenesis, International Journal of Biological Sciences, Human Genetics, Journal of Dermatological Science, Clinical Genetics, Journal of Cell Science

***Ad hoc reviewer for scientific meetings***

2007 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Zurich, Switzerland, September 5-8, 2007.  
2008 Abstract reviewer for the International Investigative Dermatology (IID) Meeting, Kyoto, Japan, May 14-17, 2008.  
2009 Abstract reviewer for the Annual Meeting of the Society of Investigative Dermatology (SID), Montreal, Canada, May 6-9, 2009.  
2009 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Budapest, Hungary, September 9-12, 2009.  
2010 Abstract reviewer for the Annual Meeting of the Society of Investigative Dermatology (SID), Atlanta, Georgia, May 5-8, 2010.

- 2010 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Helsinki, Finland, September 8-11, 2010.
- 2011 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Barcelona, Spain, September 7-10, 2011.
- 2012 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Venice, Italy, September 19-22, 2012.
- 2015 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Rotterdam, The Netherlands, September 9-12, 2015.

### **INVITED LECTURES**

#### ***Scientific audience***

- 2005 The Netherlands Cancer Institute, Amsterdam, The Netherlands. "The role of p63 in epidermal morphogenesis"
- 2006 University of Colorado at Denver and Health Sciences Center, Aurora, CO. "The role of p63 in epidermal morphogenesis"
- 2008 Experimental Biology Meeting, San Diego, CA. "p63 induces key target genes required for epidermal morphogenesis"
- 2008 The International Symposium on Olfaction and Taste, San Francisco, CA. "Transcriptional control of epidermal morphogenesis"
- 2008 National Jewish Health, Denver, CO. "The role of p63 in epidermal development and differentiation"
- 2009 Montagna Symposium on the Biology of Skin, Gleneden Beach, OR. "The role of p63 in skin development and ectodermal dysplasias".
- 2009 Colorado State University, Fort Collins, CO. "The role of p63 in skin development and ectodermal dysplasias".
- 2010 Annual Meeting of the Society for Investigative Dermatology, Atlanta, GA. State-of-the-Art lecture: "Skin Development and Disease: The p63 Story".
- 2010 University of Nebraska Medical School, College of Dentistry, Lincoln, NE. "Ectodermal dysplasias: the biology of skin, hair, and tooth abnormalities".
- 2011 Jikei University School of Medicine, Tokyo, Japan. "p63 in normal skin biology and disease"
- 2011 Meeting of the Japanese Society for Investigative Dermatology (JSID), Kyoto, Japan. "The cellular and molecular basis for hair abnormalities in AEC patients".
- 2012 Ectodermal Dysplasia Classification Conference, Charleston, SC. "AEC - New Approaches to Disease Modeling and Treatment Design"
- 2013 Emory University, Atlanta, GA. "p63 in normal skin biology and disease"
- 2013 Vanderbilt University, Nashville, TN. "p63 in normal skin biology and disease"
- 2013 Annual meeting of the Wound Healing Society (WHS), Denver, CO. "p63 in normal skin biology and disease"
- 2013 University of Cologne, Cologne, Germany. "p63 in normal skin biology and disease"
- 2014 Colorado State University, Fort Collins, CO. "p63-related ectodermal dysplasias"
- 2014 UC Denver, Aurora, CO; Global Skin Disease Research Consortium Summer School. "Advantages and limitations of using mouse models in biomedical research"
- 2014 University of Turku, Turku, Finland. "p63 in normal skin biology and disease"
- 2015 Colorado State University, Fort Collins, CO. 2015 CSU Stem Cell Biotherapy Colloquium. "Designing Stem Cell-Based Models and Therapies for Ectodermal Dysplasias"

- 2015 Annual meeting of the Society for Investigative Dermatology, Atlanta, GA. "Ectodermal dysplasias: new approaches to disease modeling and treatment design"
- 2015 University of Colorado Cancer Center, Aurora, CO. "p63: oncogene or tumor suppressor?"
- 2015 Mucosal Inflammation Program, University of Colorado Denver, Aurora, CO. "p63 in normal skin biology and disease"
- 2015 NIH Ectodermal Dysplasia Workshop, Bethesda, MD. "Designing Stem Cell-Based Models and Therapies for Ectodermal Dysplasias"
- 2015 Annual Skin Research Retreat, Boulder, CO. "The Molecular Pathology of Ectodermal Dysplasias Caused by TP63 Mutations"
- 2015 Global Skin Disease Research Consortium (GSDRC) Symposium, Tokyo, Japan. "Dissecting transcriptional networks that control hair follicle stem cells"
- 2016 Northwestern University, Chicago, IL. "p63-Mediated Control of Ectodermal Stem Cell Fate and Cancer"
- 2017 Ectodermal Dysplasia Workshop, NIH, Bethesda, MD "Molecular mechanisms underlying tissue fragility in TP63-related ectodermal dysplasias"
- 2017 Ectodermal Dysplasia Classification Workshop, Bethesda, MD "Ectodermal dysplasia classification proposal"
- 2017 National Foundation for Ectodermal Dysplasias (NFED) Family Conference, Falls Church, VA. "p63 in limbal stem cell deficiency"
- 2017 University of Iceland, Reykjavik. "The molecular pathology underlying TP63-related ectodermal dysplasias"
- 2018 University of Dayton, Dayton, OH. "The many roles of p63: from growing a feather to sprouting a tumor"

**Lay audience**

- 2008 Kiwanis Club of Aurora, Aurora, CO. "Stem Cells"
- 2008 American Association of University Women (AAUW), Aurora, CO. "The latest in stem cell research"
- 2009 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, Williamsburg, VA. "Ectodermal Dysplasia Research"
- 2010 American Association of University Women (AAUW), Aurora, CO. "An update on stem cell research under the Obama administration"
- 2010 Colorado State Convention of the American Association of University Women (AAUW), Aurora, CO. "Stem Cell Research"
- 2010 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, Colorado Springs, CO. "Treatment Design for Ectodermal Dysplasias"
- 2010 American Civil Liberties Union (ACLU)/Pro Families, Pro Choice (PFPC), Denver, CO. "Stem Cell Research and its Relationship to the Proposed Personhood Amendment"
- 2011 Fourth Annual Math Day for Girls, Aurora, CO. "Science Rocks!"
- 2011 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, O'Fallon, IL. "AEC Research"
- 2012 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, Orlando, FL. "Update on p63 Research"
- 2013 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, Houston, TX. "p63 Research Update"

- 2014 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, Columbus, OH. "p63 Research Update"
- 2016 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, St. Louis, MO. "p63 Research Update"
- 2017 NFED research fundraising campaign, New York City, NY. "AEC research"
- 2017 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, Falls Church, VA. "p63 Research Update"
- 2019 National Foundation for Ectodermal Dysplasias (NFED) National Family Conference, Lincolnshire IL. "p63 Research Update"

## **TEACHING**

### ***Grand Rounds***

- 2010 University of Colorado Denver Dermatology Grand Rounds sponsored by the National Foundation for Ectodermal Dysplasias, Denver, CO. "AEC Research".
- 2011 St Louis University School of Medicine, St Louis, MO. Grand Rounds: "Towards a cure for skin erosions in AEC patients".
- 2013 Emory University, Atlanta, GA. Grand Rounds: "Ectodermal dysplasias: new approaches to disease modeling and treatment design"
- 2013 Vanderbilt University, Nashville, TN. Grand Rounds: "Ectodermal dysplasias: new approaches to disease modeling and treatment design"

### ***Lectures in Undergraduate Courses***

- 2008-2010 Undergraduate students, University of Colorado Denver, BIOL 4050/5050 Advanced Topics: Stem Cell Biology.  
"Using Transgenic Mice to Study Stem Cells"
- 2017 Undergraduate students, University of Iceland. Topic: "Ectodermal Dysplasias".

### ***Lectures in Graduate Courses***

- 2008-2010 Graduate students, University of Colorado Denver, CDBI 7605, Developmental Biology. Topic: "Epithelial Stem Cells"
- 2009-current Graduate students, University of Colorado Denver, IDPT 7646, Tissue Biology and Disease Mechanism.  
Topic: "Skin Biology"
- 2011-2012 Graduate students, University of Colorado Denver, CSDV 7605, Stem Cells and Development: An Integrated Approach.  
Topic: "Induced Pluripotent Stem Cells" [co-taught with Dr. Peter Koch]
- 2011 Graduate students, University of Colorado Denver, CSDV 7670, Stem Cells and Stem Cell Technology in Biomedical Research.  
Topics: "Introduction to Stem Cells" and "Tracing Stem Cell Fate in Vivo"
- 2014 Graduate students (from various national and international institutions), GSDRC Summer School 2014, University of Colorado Denver,  
Topic: "Advantages/limitations of using mouse models in biomedical research".
- 2017-current Graduate students, University of Colorado Denver, IDPT 7810, Stem Cell Biology to Regenerative Medicine. Topics: "Stem cell basics", "skin, hair follicle, and cornea stem cells", "label retaining cells" [multi-day laboratory exercise].

**Lectures to Dermatology Residents**

- 2007-2011 Dermatology residents, University of Colorado Denver.  
Topics: "Modeling Ectodermal Dysplasias" and "Molecular Biology Techniques"
- 2013 Dermatology residents, Emory University, Atlanta, GA.  
Topic: "Treatment approaches for inherited skin disorders"
- 2013 Dermatology residents, Vanderbilt University, Nashville, TN.  
Topic: "Treatment approaches for inherited skin disorders"
- 2016, 2017 Dermatology residents, University of Colorado Denver.  
Topic: "Modeling Ectodermal Dysplasias"

**Lectures to Law Students**

- 2010, 2012 Law students, Washburn University (Topeka, KS), LW 860, Bioethics, Topic: Stem Cell Research.  
Topic: "Stem Cell Research"

**Course/Program Organizer**

- 2008 Graduate students, University of Colorado Denver, BSP seminar (journal club-style class), "Advances in Stem Cell Research"; **Course co-director.**

The objective of this course, co-directed by Dr. Peter Koch and myself, was to teach first year graduate students to read and interpret scientific literature. In this 5-week journal club, each student was asked to discuss one paper related to stem cell research.

- 2011 Graduate students, University of Colorado Denver, CSDV7670 "Stem Cells and Stem Cell Technology in Biomedical Research". **Course co-director.**

This advanced graduated course was offered in Spring 2011 and co-directed by Dr. Peter Koch and myself. The goal of this course was to provide students with an overview of the biology of different types of stem cells. The course also provided an overview of the applications of stem cell technology, both in basic research as well as in the clinic. Finally, the course contained several demos aimed at illustrating the use of stem cells in the laboratory.

- 2014 GSDRC Summer School 2014. **Organizer.**

The GSDRC is a consortium of the University of Cologne (Cologne, Germany), Columbia University Medical Center (New York, USA), Keio University School of Medicine (Tokyo, Japan), the University of Colorado Denver (Aurora, USA), Dundee University (Scotland, UK), and the Skin Research Institute of Singapore (Singapore). I serve as the coordinator for the University of Colorado Denver Site. In that capacity, I organized the educational and social programs for the first GSDRC summer school held July 28-30, 2014, at the Anschutz Medical Campus. This summer school was attended by twenty-eight graduate students and postdoctoral fellows representing the six member institutions. The primary focus of the summer school was the design of appropriate models to study skin diseases, and included lectures on stem cell-based modeling of skin diseases, animal models for skin diseases, and stem cell-based therapies.

2016 Graduate students, University of Colorado Denver, CSDV7670 "Stem Cells and Stem Cell Technology in Biomedical Research". **Course co-director.**

This advanced graduated course was offered in Spring 2016 and co-directed by Dr. Peter Koch and myself. The goal of this course was to provide students with an overview of the biology of different types of stem cells. The course also provided an overview of the applications of stem cell technology, both in basic research as well as in the clinic. Finally, the course contained several demos aimed at illustrating the use of stem cells in the laboratory.

2017 - 2019 Graduate students, University of Colorado Denver, IDPT7810 "Stem Cell Biology to Regenerative Medicine". **Course co-director.**

This 2-credit graduate course was offered in Fall 2017 as part of the Core curriculum for first year graduate students. The course was co-directed by Dr. Peter Koch and myself. The goal of this course was to provide students with an overview of the biology of different types of stem cells. The course also provided an overview of the applications of stem cell technology, both in basic research as well as in the clinic. Finally, the course offered a laboratory exercise aimed at identifying stem cells in different tissues and several demos aimed at illustrating the use of stem cells in the laboratory.

### Trainees

#### **Postdoctoral Fellows**

- 2009-2015 Velmurugan Balaiya, PhD  
Currently a research associate in the Koster lab
- 2012-2013 Ganna Liubchenko, PhD  
Currently a scientist in the Department of Molecular Biology, Biotechnology, and Biophysics at the Taras Shevchenko National University of Kyiv (Ukraine).
- 2013-2016 Sangeeta Shrotriya, PhD, BCMAS  
Currently Clinical Research Lead at Terumo BCT (Lakewood, CO). Terumo BCT is developing and testing technologies to increase clinical applications of blood products.

#### **Graduate Students**

- 2014-2018 Senthilnath Lakshmanachetty, PhD, CSD program, University of Colorado Denver  
"Identifying molecular mechanisms that contribute to skin squamous cell carcinoma development and progression"  
Currently a postdoctoral fellow in the laboratory of Dr. Siddhartha Mitra at the University of Colorado – Anschutz Medical Campus
- 2017-2018 Marc Steingesser, BS, CSD program, University of Colorado Denver  
"Identifying molecular mechanisms that underlie limbal stem cell deficiency in inherited tissue fragility disorders". Student left PhD program prior to initiating thesis project
- 2018-current Christina Sheldon, BS, Bioengineering Program, University of Colorado Denver  
"Using atomic force microscopy to identify cell adhesion forces in keratinocytes expressing mutant TP63" (co-mentored with Dr. Peter Koch)

**Graduate Student Committees**

**Chair**

2012-2017 Jason Dinella, CSD program, University of Colorado Denver  
“Determining the biological basis of AEC (Ankyloblepharon Ectodermal Dysplasia and Clefting) and the development of iPS cell-based therapeutic strategies to ameliorate skin fragility in AEC patients”

**Committee Member**

2007 – 2008 Irene Choi, MS, CSD program, University of Colorado Denver  
Obtained MS degree prior to deciding on thesis project

2008 – 2012 Aaron Huebner, PhD, CSD program, University of Colorado Denver  
“Consequences of loricrin deficiency on epidermal barrier formation and function”

2008 – 2012 Francie Barron (Hyndman), PhD, CSD program, University of Colorado Denver  
“The Role of Hand2, a basic helix-loop-helix transcription factor, in mouse craniofacial development”

2009 -2010 Rebecca Echols, MS, Pharmaceutical Sciences Program, University of Colorado Denver  
Obtained MS degree prior to deciding on thesis project

2011 – 2012 Erin McKinsey, MS, Cancer Biology Program, University of Colorado Denver  
“The Role of miR-100 in Ewing’s Sarcoma Pathogenesis”  
Student left graduate program with MS degree to pursue other interests

2013 - 2017 Xi Chen, Cancer Biology Program, University of Colorado Denver  
“PI3K-dependent and –independent mechanisms in maintaining stemness of cancer stem cells”

2014 - 2019 Lynsey Fettig, BS, Cancer Biology Program, University of Colorado Denver  
“Investigating the role of progesterone and its cognate receptors in expansion of the breast cancer stem cell population in luminal disease”

2015-2017 Melissa Tjandra, Biomedical Sciences and Biotechnology Program (MS program), University of Colorado Denver  
“Analyzing the effects of mutations in the transcription factor TP63 on keratinocyte differentiation.”

2017 - current Olivia McGinn, BS, Cancer Biology Program, University of Colorado Denver  
“Investigating the Relationship of CK5 with the Mevalonate Pathway and Beta-catenin in Luminal Breast Cancer Stem Cell Maintenance”

**Undergraduate Interns**

2014 Delaney Kriz, Oregon State University

2016 Marc Steingesser, University of Maryland Baltimore

2016-2017 Cory Jonak, University of Missouri

2019 Peter Johnson, Virginia Wesleyan University

***Dermatology Residents***

2009 – 2012 Renata Prado, MD

2009 – 2012 Valerie Joncas, MD

Drs. Prado and Joncas performed a research project in the laboratory aimed at identifying the genetic mutation in a patient they encountered in the dermatology clinic. They further characterized the disease at the cellular/molecular level.

**GRANT SUPPORT**

**Active**

R21 EY029081

Koster and Koch (PIs, Multi-PI Grant)

08/01/19-07/31/21

NIH/NEI

\$233,250 per year (\$150,000 direct + \$83,250 indirect)

Trp63 in limbal stem cell deficiency

The goal of this grant is to identify mechanisms by which mutant Trp63 proteins lead to limbal stem cell deficiency in patients affected by ectodermal dysplasias.

Role: PI

R01 AR072621

Koster and Koch (PIs, Multi-PI Grant)

10/01/17-09/30/22

NIH/NIAMS

\$457,366 per year (\$294,126 direct + \$163,240 indirect)

Mechanisms underlying tissue fragility in ectodermal dysplasias

The goal of this grant is to define molecular mechanisms by which mutant TP63 proteins cause tissue fragility in ectodermal dysplasias.

Role: PI

**Pending**

Rare as One Network

Fete, Wright, and Koster (PIs)

01/01/20–12/31/21

Chan Zuckerberg Initiative

\$225,000 per year (for the entire project)

The goal of this grant is to establish an international research network to advance and accelerate research into ectodermal dysplasias, a group of rare genetic disorders. The three co-PIs bring in different expertise in terms of advocacy (Fete), clinical expertise (Wright), and research (Koster).

Role: Research PI

**Completed**

P30 AR057212

Norris (PI)

09/28/09-07/31/19

NIH/NIAMS

\$124,190 per year (\$80,123 direct + \$44,067 indirect)

Molecular Analysis, Modeling and Correction of Skin Diseases

The goal of this multi-investigator grant is to provide Core support and support for pilot projects for investigators interested in skin biology and skin diseases. This grant provides support for the Morphology and Phenotyping Core, directed by Dr. Koster.

Role: Core director [the budget listed is the budget allocated to the Core]

National Foundation for  
Ectodermal Dysplasias

Koster and Koch (PIs)

10/01/17-09/30/18

\$25,000

Trp63 in limbal stem cell deficiency

The goal of this grant is to analyze the function of mutant Trp63 proteins in the limbal stem cells of the cornea.

Role: PI

R56 AR066713 Koster and Koch (Co-PI) 09/17/14-08/31/16  
 NIH/NIAMS \$458,099 per year (\$303,190 direct + \$154,909 indirect)  
 Elucidating the molecular pathology of ectodermal dysplasias caused by TP63 mutations  
 The goal of this grant is to define molecular mechanisms by which mutant TP63 proteins cause skin abnormalities in ectodermal dysplasias.  
 Role: PI

R01 AR061506 Koster (PI) 07/21/11-06/30/16  
 NIH/NIAMS \$334,710 per year (\$225,000 direct + \$109,710 indirect)  
 The role of p63 in hair follicle stem cells and cancer  
 The goal of this grant is to determine the role of p63 in hair follicle stem cells both under homeostatic and under pathological conditions.  
 Role: PI

R21 HL113961 Reynolds (PI) 07/01/13-06/30/15  
 NIH \$38,750 per year (\$25,000 direct + \$13,750 indirect)  
 Identification of tracheobronchial basal cell-specific genes  
 The goal of this grant is to identify genes that are specifically expressed in the tracheobronchial epithelium and the epidermis. Ultimately, this will lead to the development of cell- and tissue-specific drivers for use in generating mouse models.  
 Role: Subcontract

Cancer League of Colorado Koster (PI) 07/01/14-06/30/15  
 \$30,000  
 Consequences of TP63 loss on human skin squamous cell carcinogenesis  
 The goal of this grant is to determine the role of the transcription factor TP63 in the development and progression of human skin squamous cell carcinomas.  
 Role: PI

National Foundation for Ectodermal Dysplasias Koster and Koch (Co-PI) 08/01/14-07/31/15  
 \$25,000  
 Developing methods for generating full-thickness, healthy, replacement skin for AEC patients  
 The goal of this grant is to optimize methods for the generation of skin derived from pluripotent stem cells obtained from AEC patients.  
 Role: PI

National Foundation for Ectodermal Dysplasias Koster and Koch (Co-PI) 04/01/12-03/31/13  
 \$25,000  
 Developing therapeutic tools for correcting AEC mutations in patient cells  
 The major goal of this project is to correct mutations in patient-derived iPS cells and to determine the feasibility of using an iPS cell-based therapy to treat skin erosions in AEC patients.  
 Role: PI

K99/R00 AR054696 Koster (PI) 08/01/07-07/31/12  
 NIH/NIAMS K99 phase (YR1-2): \$90,000 per year (\$83,760 direct + 6,240 indirect)  
 R00 phase (YR3-5): \$249,000 per year (\$165,678 direct + \$83,322 indirect)  
 The role of p63 in normal epidermal differentiation and ectodermal dysplasias

The major goal of this grant is to identify regulatory pathways by which p63 controls epidermal differentiation and to determine the pathogenic mechanisms underlying skin fragility disorders caused by p63 mutations.

Role: PI

<u>National Foundation for Ectodermal Dysplasias</u>	Koster and Koch (Co-PI) \$25,000	04/01/11-03/31/12
--	-------------------------------------	-------------------

Towards a cure for skin erosions in AEC patients

The major goal of this project is to determine the feasibility of using an iPS cell-based therapy to treat skin erosions in AEC patients.

Role: PI

<u>National Foundation for Ectodermal Dysplasias</u>	Koster (PI) \$25,000	04/01/09-03/31/11
--	-------------------------	-------------------

Is AEC caused by defective skin stem cells?

The major goal of this project is to determine if interfollicular and/or hair follicle stem cells are defective in AEC patients.

Role: PI

<u>American Skin Association</u>	Koster (PI) \$15,000	03/01/09-09/28/10
----------------------------------	-------------------------	-------------------

Elucidating the role of p63 in the development of squamous cell carcinomas

The major goal of this grant is to determine whether interfollicular and/or hair follicle stem cells contribute to SCC development in the absence of p63.

Role: PI

<u>Strategic Infrastructure for Research Committee (UCD)</u>	Koster (PI) \$12,997	11/24/2009
--	-------------------------	------------

Cryostat for Morphology and Phenotyping Core

The goal of this application was to obtain funding for a cryostat for the Morphology and Phenotyping Core, directed by Dr. Koster.

Role: PI

<u>National Foundation for Ectodermal Dysplasias</u>	Koster and Roop (Co-PI) \$25,000	04/01/07-03/31/08
--	-------------------------------------	-------------------

Characterization of the role of Fras1, a novel  $\Delta Np63\alpha$  target gene, in AEC

The major goal of this project is to characterize the role of the basement membrane protein Fras1 in normal epidermis, and to determine the contribution of reduced Fras1 expression to skin fragility in AEC patients.

Role: PI

<u>National Foundation for Ectodermal Dysplasias</u>	Koster and Roop (Co-PI) \$25,000	04/01/06-03/31/07
--	-------------------------------------	-------------------

Identification of novel  $\Delta Np63\alpha$  target genes that contribute to AEC/RHS

The major goal of this project is to identify novel target genes of  $\Delta Np63\alpha$  that contribute to skin fragility in AEC patients.

Role: PI

## **PUBLICATIONS**

### **Primary papers:**

1. Liefer, K.M., Koster, M.I., Wang, X.J., Yang, A., McKeon, F., and Roop, D.R. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. *Cancer Res.* 60(15):4016-20, 2000.
2. Koster, M.I., Kim, S., Mills, A.A., DeMayo, F.J., and Roop, D.R. p63 is the molecular switch for initiation of an epithelial stratification program. *Genes Dev.* 18(2):126-31, 2004.
3. Koster, M.I., Kim, S., Huang, J., Williams, T., and Roop, D.R. TAp63 $\alpha$  induces AP-2 $\gamma$  as an early event in epidermal morphogenesis. *Dev Biol.* 289(1): 253-261, 2006.
4. Honeycutt, K.A., Chen, Z., Koster, M.I., Miers, M., Nuchtern, J., Hicks, J., Roop, D.R., and Shohet, J.M. Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. *Oncogene* 25(29):4027-32, 2006.
5. Nguyen, B.C., Lefort, K., Mandinova, A., Antonini, D., Devgan, V., Della Gatta, G., Koster, M.I., Zhang, Z., Wang, J., Tommasi di Vignano, A., Kitajewski, J., Chiorino, G., Roop D.R., Missero, C., and Dotto, G.P. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. *Genes Dev.* 20(8):1028-42, 2006.
6. Koster, M.I., Lu, S.L., Wang, X.J., and Roop, D.R. Reactivation of developmentally expressed p63 isoforms accelerates tumor development and progression. *Cancer Res.* 66(8):3981-6, 2006.
7. Keyes, W.M., Vogel, H., Koster, M.I., Guo, X., Qi, Y., Petherbridge, K.M., Roop, D.R., Bradley, A., and Mills, A.A. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. *Proc Natl Acad Sci U S A.* 103(22):8435-40, 2006.
8. Koster, M.I., Dai, D., Marinari, B., Sano, Y., Costanzo, A., Karin, M., and Roop, D.R. p63 induces key target genes required for epidermal morphogenesis. *Proc Natl Acad Sci USA*, 104(9):3255-60, 2007.
9. Shah, V.R., Koster, M.I., Roop, D.R., Spencer, D.M., Wei, L., Li, Q., Shwartz, R.J., and Chang, J. Double-inducible gene activation system for caspase 3 and 9 in epidermis. *Genesis* 45(4): 194-199, 2007.
10. Guttormsen, J., Koster, M.I., Stevens, J.R., Roop, D.R., Williams, T., and Winger, Q.A. Disruption of epidermal specific gene expression and delayed skin development in AP-2 $\gamma$  mutant mice. *Dev Biol.*, 317(1):187-95, 2008.
11. Marinari, B., Ballaro, C., Koster, M.I., Giustizieri, M.L., Moretti, F., Crosti, F., Karin, M., Alema, S., Chimenti, S., Roop, D.R., and Costanzo, A. IKK $\alpha$  is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias. *J Invest Dermatol*, 105:17091-6, 2008.
12. Takeda, K., Okamoto, M., de Langhe, S., Dill, E., Armstrong, M., Reisdorf, N., Irwin, D., Koster, M., Wilder, J., Stenmark, K.R., West, J., Klemm, D., Gelfand, E.W., Nozik-Grayck, E., Majka, S.M. Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. *Anat Rec*, 292(7):1045-61, 2009.
13. Koster, M.I., Marinari, B., Payne, A.S., Kantaputra, P.N., Costanzo, A., and Roop, D.R.  $\Delta$ Np63 knockdown mice: a mouse model for AEC syndrome. *Am J Med Genet A*, 9:1942-1947, 2009.
14. Beaudry, V.G., Pathak, N., Koster, M.I., and Attardi, L.D. Differential Perp regulation by p63 mutants provides insights into AEC pathogenesis. *Am J Med Genet A*, 9:1952-1957, 2009.
15. Fete, M., van Bokhoven, H., Clements, S., McKeon, F., Roop, D.R., Koster, M.I., Missero, C., Attardi, L.D., Lombillo, V.A., Ratovitski, E., Julapalli, M., Ruths, D., Sybert V.P., Siegfried, E.C., and Bree, A.F. Conference report: International research symposium on Ankyloblepharon Ectodermal Defects-Cleft Lip and/or Palate (AEC) Syndrome. *Am J Med Genet A*, 9:1885-1893, 2009.
16. Kim, S., Choi, I.F., Quante, J.R., Zhang, L., Roop, D.R., and Koster, M.I. p63 directly induces expression of Alox12, a regulator of epidermal barrier formation. *Exp Dermatol*, 18(12):1016-21, 2009.

17. Honeycutt, K.A., Waikel, R., Koster, M.I., Wang, X-J, and Roop, D.R. The effect of c-Myc on stem cell fate influences tumor phenotype. *Mol Carcinog*, 49(4):315-9, 2010.
18. Chen, J., O’Shea, C., Fitzpatrick, J.E., Koster, M.I., and Koch, P.J. Loss of desmocollin 3 in skin tumor development and progression. *Mol Carcinog*, 51(7):535-45, 2011.
19. Ferone, G., Thomason, H.A., Antonini, D., De Rosa, L., Hu, B., Gemei, M., Zhou, H., Ambrosio, R., Rice, D., Acampora, D., van Bokhoven, H., Del Vecchio, L., Koster, M.I., Tadini, G., Spencer-Dene, B., Dixon, M., Dixon, J., and Missero, C. Mutant p63 causes defective expansion of ectodermal progenitor cells and impaired FGF signaling in AEC syndrome. *EMBO Mol Med*, 4(3):192-205, 2012.
20. Tao, J., Koster, M.I., Harrison, W., Moran, J.L., Beier, D.R., Roop, D.R., and Overbeek, P.A. A spontaneous *Fatp4/Sc127a4* splice site mutation in a new murine model for congenital ichthyosis. *PLoS ONE*, 2012;7(11):e50634.
21. Chari, N.S., Romano, R.A., Koster, M.I., Jaks, V., Roop, D., Flores, E.R., Teglund, S., Sinha, S., Gruber, W., Aberger, F., Medeiros, L.J., Toftgard, R., and McDonnell, T.J. Interaction between the TP63 and SHH pathways is an important determinant of epidermal homeostasis. *Cell Death Differ*, 20(8): 1080-1088, 2013. PMID: PMC3705600.
22. Koster, M. I., Dinella, J., Chen, J., O’Shea, C., and Koch, P.J. Integrating animal models and in vitro tissue models to elucidate the role of desmosomal proteins in diseases. *Cell Commun Adhes*, 21(1):55-63, 2014. PMC Journal - In Process
23. Koch, P.J., Dinella, J., Fete, M., Siegfried, E.C., and Koster, M. I. Modeling AEC – New approaches to study rare genetic disorders. *Am J Med Genet A*, 164A:2443-2454, 2014.
24. Goldstein, N.B., Koster, M.I., Hoaglin, L.G., Spoelstra, N.S., Kechris, K.J., Robinson, S.E., Robinson, W.A., Roop, D.R., Norris, D.A., and Birlea, S.A. Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors. *J Invest Dermatol*, 135:2068-76, 2015.
25. Goldstein, N.B., Koster, M.I., Hoaglin, L., Wright, M., Robinson, S., Robinson, W., Roop, D.R., Norris, D.A., and Birlea, S.A. Isolating RNA from precursor and mature melanocytes from human vitiligo and normal skin using laser capture microdissection. *Exp. Dermatol*, 25:805-11, 2016.
26. Goldstein, N.B., Koster, M.I., Jones, K.L., Gao, B., Hoaglin, L.G., Robinson, S.E., Wright, M.J., Birlea, S.I., Luman, A., Lambert, K.A., Shellman, Y.G., Fujita, M., Robinson, W.A., Roop, D.R., Norris, D.A., and Birlea, S.A. Repigmentation of Human Vitiligo Skin by NB-UVB Is Controlled by Transcription of *GLI1* and Activation of the  $\beta$ -Catenin Pathway in the Hair Follicle Bulge Stem Cells. *J Invest Dermatol*. 138:657-668, 2018.
27. Dinella, J.D., Chen, J., Webb, S., Siegfried, E., Bree, A.F., Lakshmanachetty, S., Balaiya, V., Koster, M.I.\*, and Koch, P.J\*. A Human Stem Cell-Based System to Study the Role of TP63 Mutations in Ectodermal Dysplasias. *J Invest Dermatol*, 138:1662-1665, 2018. \* denotes equal contribution.
28. Lakshmanachetty, S., Balaiya, V., Johnson, L., and Koster, M.I. “TRP63/TP63 loss accelerates skin tumorigenesis through activation of Wnt/ $\beta$ -catenin signaling”. *J Dermatol Sci*. 91:325-328, 2018.
29. Wright, T., Fete, M., Schneider, H., Zinser, M., Koster, M.I., Clarke, A.J., Hadj-Rabia, S., Tadini, G., Pagnan, N., Visinoni, A.F., Bergendahl, B., Abbott, B., Fete, T., Stanford, C., Butcher, C., D’Souza, R., and Sybert, V. “Ectodermal dysplasias: Classification and organization by phenotype, genotype and molecular pathway”. *Am J Med Genet A*. doi: 10.1002/ajmg.a.61045. [Epub ahead of print], 2019.
30. Lakshmanachetty, S., Balaiya, V., High, W.A., and Koster, M.I. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling. *Mol Cancer Res*. 17:1279-1293, 2019.

Reviews:

31. Koster, M.I., Huntzinger, K.A., and Roop, D.R. Epidermal differentiation: transgenic/knockout mouse models reveal genes involved in stem cell fate decisions and commitment to differentiation. *J Investig Dermatol Symp Proc.* 7(1):41-5, 2002.
32. Li, A.G., Koster, M.I., and Wang, X.J. Roles of TGF $\beta$  signaling in epidermal/appendage development. *Cytokine Growth Factor Rev.* 14(2):99-111, 2003.
33. Koster, M.I. and Roop, D.R. The role of p63 in development and differentiation of the epidermis: Tanioku Kihei memorial lecture. *J Dermatol Sci.* 34(1):3-9, 2004.
34. Koster, M.I., and Roop, D.R. Transgenic mouse models provide new insights into the role of p63 in epidermal development. *Cell Cycle* 3(4):411-413, 2004.
35. Honeycutt, K.A., Koster, M.I., and Roop, D.R. Genes involved in stem cell fate decisions and commitment to differentiation play a role in skin disease. *J Investig Dermatol Symp Proc.*, 9(3):261-8, 2004.
36. Koster, M.I. and Roop, D.R. Genetic pathways required for epidermal morphogenesis. *Eur J Cell Biol.* 83(11-12):625-9, 2004.
37. Koster, M.I. and Roop, D.R. p63 and epithelial appendage development. *Differentiation* 72(8):364-70, 2004.
38. Koster, M.I., Kim, S., and Roop, D.R. p63 Deficiency: a failure of lineage commitment or stem cell maintenance? *J Investig Dermatol Symp Proc.*, 10(2):118-23, 2005.
39. Koster, M.I., Dai, D., and Roop, D.R. Conflicting roles for p63 in skin development and carcinogenesis. *Cell Cycle* 6(3):269-273, 2007.
40. Koster, M.I. and Roop, D.R. Mechanisms regulating epithelial stratification. *Ann Rev Cell Dev Biol.*, 23:93-113, 2007.
41. Koster, M.I. Making an epidermis. *Ann. N.Y. Acad. Sci.* 1170: 7-10, 2009.
42. Koster, M.I. p63 in skin development and ectodermal dysplasias. *J Investig Derm*, 130:2352-2358, 2010.
43. Dinella, J., Koster, M.I., and Koch, P.J. Use of Induced Pluripotent Stem Cells in Dermatological Research. *J Invest Dermatol*, 134(8):1-5, 2014.
44. Koster, M.I., Dinella, J., Chen, J., O'Shea, C., and Koch, P.J. Integrating animal models and in vitro tissue models to elucidate the role of desmosomal proteins in diseases. *Cell communication & adhesion*, 21(1):55-63, 2014.
45. Koch, P.J., Dinella, J., Fete, M., Siegfried, E.C., and Koster, M.I. Modeling AEC-New approaches to study rare genetic disorders. *American journal of medical genetics, part A.* 164A(10):2443-54, 2014.

Commentaries:

46. Koster, M.I. and Roop, D.R. Asymmetric cell division in skin development: a new look at an old observation. *Dev Cell* 9(4):444-6, 2005.
47. Koster, M.I. and Roop, D.R. Sorting out the p63 signaling network. *J Investig Dermatol* 128(7):1617-9, 2008.
48. Koster, M.I. Building models for keratin disorders. *J Investig Dermatol* 132(5):1324-6, 2012.
49. Lakshmanachetty, S. and Koster, M.I. Emerging roles for collagen XV and XVIII in cancer progression. *Exp Derm*, 25:346-7, 2016.

Letters to the Editor:

50. Mikkola, M.L., Costanzo, A., Thesleff, I., Roop, D.R., and Koster, M.I. Treasure or Artifact: A Decade of p63 Research Speaks for Itself. *Cell Death Differ*, 17(1):180-183, 2010.

Book Chapters:

51. Arin, M.J., Roop, D.R., Koch, P.J., and Koster, M.I. Biology of Keratinocytes, Chapter 55. In: Dermatology 1<sup>st</sup> Edition; Editors: J.L. Bologna, J.L. Jorizzo, and R.P. Rapini, 2008.
52. Roop, D.R. and Koster, M.I. p63 in squamous differentiation and cancer. In: Signaling Pathways in Squamous Cancer, Chapter 12, p241-259; Editors: Adam Glick and Carter Van Waes, 2010.
53. Arin, M.J., Roop, D.R., Koch, P.J., and Koster, M.I. Biology of Keratinocytes, Chapter 56. In: Dermatology, 2<sup>nd</sup> Edition; Editors: J.L. Bologna, J.L. Jorizzo, and R.P. Rapini, 2012.
54. Koster, M.I., Loomis, C.A., Koss, T., Chu, D. Skin Development and Maintenance, Chapter 2. In: Dermatology 2<sup>nd</sup> Edition; Editors: J.L. Bologna, J.L. Jorizzo, and R.P. Rapini, 2012.
55. Arin, M.J., Roop, D.R., Koch, P.J., and Koster, M.I. Biology of Keratinocytes, Chapter 56. In: Dermatology, 3<sup>rd</sup> Edition; Editors: J.L. Bologna, J.V. Schaffer, and L. Cerroni, 2015.
56. Arin, M.J., Roop, D.R., Koch, P.J., and Koster, M.I. Biology of Keratinocytes, Chapter 56. In: Dermatology, 4<sup>th</sup> Edition; Editors: J.L. Bologna, J.V. Schaffer, and L. Cerroni, 2017.

**EAST CAROLINA UNIVERSITY PERSONNEL ACTION SUMMARY FORM**  
*(Administrator completes Section I. and faculty member (appointee) completes Section II.)*

Section I. To be completed by the appropriate administrator(s).

Name of Appointee: **Maranke Koster, PhD**

Department: **Anatomy and Cell Biology**

School/College: **BSOM, ECU**

Current Rank or Title: *(if applicable)* Proposed Rank or Title: **Professor**

Indicate Type of Action: *(select all that apply)*

Administrative Appointment:

New Faculty Appointment:

Promotion:

Conferral of Tenure:

Other:  
*(describe)*

Distinguished Professorship:  
*(provide name of professorship)*

Effective Date of Action: **February 23, 2020**

Contract Period: Administrative Appointment: 9 mo.  12 mo.   
 Faculty Appointment: 9 mo.  12 mo.

Salary: **\$166,000** Source(s): State Funds: **\$0** \*Non-State Funds: **\$166,000**

*\*Indicate Sources of non-state funds generically ( i.e., grants, receipts, trust funds, endowments, medical faculty practice plan, etc.):*

Prior Recommendations/Personnel Actions:  
*(please check appropriate responses)*

Source	Recommended	Not Recommended	Not Applicable
Appropriate Unit Personnel Committee	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chair/Unit Head	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Director	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Dean	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Provost/Vice Chancellor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chancellor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Board of Trustees	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**1. Education Background: (indicate degree, date earned and institution, note additional study & training)**

1994-1999 M.S., Medical Biology, VU University, Amsterdam, The Netherlands

1998-1999 Pre-Master Fellow, Laboratory of Dr. W.N. Hittelman, University of Texas M.D. Anderson Cancer Center, Houston, TX

1999-2004 Ph.D., Program in Developmental Biology, Laboratory of Dr. D.R. Roop, Baylor College of Medicine, Houston, TX

2004-2007 Postdoctoral Fellow, Department of Molecular and Cellular Biology, Laboratory of Dr. D.R. Roop, Baylor College of Medicine, Houston, TX

**2. Teaching and other professional experience: (Show inclusive dates, rank and/or title, institution or agency, and indicate first appointment at current institution with rank and any changes to date)**

2007-2013 Assistant Professor, Department of Dermatology, University of Colorado School of Medicine, Aurora, CO

2008-current Director, Morphology and Phenotyping Core, University of Colorado School of Medicine, Aurora, CO

2013-current Associate Professor, Department of Dermatology, University of Colorado School of Medicine, Aurora, Co

2016-current Associate Professor, Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO

**3. Scholarly & Creative Activities:**

<i>Type</i>	<i>Number</i>
<i>Book</i>	
<i>Abstracts</i>	
<i>Peer Reviewer</i>	
<i>Chapter</i>	6
<i>Refereed Journal Article</i>	2
<i>Other Journal Article</i>	50
<i>Juried Performance/Show</i>	
<i>Non Juried</i>	
<i>Other: Ad Hoc Reviewer</i>	18
<i>Other: Research</i>	
<i>Other: Grants Support</i>	18
<i>Other: Presentations</i>	32
<i>Other: CE Courses Presented</i>	
<i>Other: Grant Reviewer</i>	34

#### 4. Membership in professional organizations:

2007-current	Member, Gates Center for Regenerative Medicine, University of Colorado School of Medicine, Aurora, CO	Attachment E
2007-current	Member, Cell Biology, Stem Cells and Development (CSD) Graduate Program, University of Colorado School of Medicine, Aurora, CO	
2008-current	Member, Biomedical Sciences Graduate Program (BSP), University of Colorado School of Medicine, Aurora, CO	
2008-current	Member, Scientific Advisory Council, National Foundation for Ectodermal Dysplasias (NFED), Fairview Heights, IL	
2009-current	Member, University of Colorado Cancer Center (UCCC), Aurora, CO	
2009-current	Member, Colorado Clinical and Translational Sciences Institute (CCTSI)	
2010-current	Member, Intellectual and Developmental Disabilities Research Center (IDDRC), University of Colorado School of Medicine, Aurora, CO	
2006-current	The Society for Investigative Dermatology	
2009-current	National Foundation for Ectodermal Dysplasias	
2012-current	North American Hair Research Society	
University		
2007-2009	Member, Admissions Committee, CSD Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO	
2009	Co-Chair, Annual Retreat of the CSD Graduate Program, Vail, CO, October 2-3, 2009	
2010-2013	Member, Executive Committee, CSD Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO	
2010	Chair, Annual Retreat of the CSD Graduate Program, Estes Park, CO, October 1-2, 2010	
2010	Chair, Admissions Committee, CSD Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO	
2011-2018	Member, Admissions Committee, BSP Graduate Program, University of Colorado – Anschutz Medical Campus, Aurora, CO	
2012-2015	Co-Chair, Annual Retreat of the Colorado Skin Research Program, Estes Park, CO, September 7-8, 2012 and June 28-29, 2013	
National		
2009	Co-chair, Concurrent minisymposium "Hair and Cutaneous Development", Annual meeting of the Society for Investigative Dermatology (SID), Montreal, Canada, May 9, 2009	
2010	Co-chair, Concurrent minisymposium "Hair and Cutaneous Development I: Embryonic Skin Development/Stem Cell Functions", Annual meeting of the Society for Investigative Dermatology (SID), Atlanta, Georgia, May 7, 2010	
2011	Member, Organizing committee for the first annual PhD retreat held prior to the 2012 meeting of the Society for Investigative Dermatology (SID)	
2012-current	Member, Ectodermal Dysplasia Classification Committee 2013-2018 Member, Board of Directors of the Society for Investigative Dermatology (SID) International 2013-current University of Colorado Coordinator, Global Skin Disease Research Consortium (GSDRC)	

**5. Professional service on campus:**

NA

**6. Professional service off campus:****Research Activities:**

NA

**Grant Review:**

Grant review committees and study sections

- 2009-current Research Grants Council (RGC) of Hong Kong
- 2009-current National Foundation for Ectodermal Dysplasias (NFED)
- 2009, 2010 Netherlands Organisation for Scientific Research (NWO; The Netherlands)
- 2010-current Telethon Foundation (Italy) 2010 Medical Research Council (UK)
- 2011 Wellcome Trust (UK)
- 2011 NIH; Special Emphasis Panel/Scientific Review Group 2011/05 ZRG1 EMNR-C (02) M
- 2011 The National Science Foundation (NSF)
- 2012, 2013 NYSTEM (New York State Stem Cell Science), Stem Cell Differentiation and Lineage panel
- 2012 Deutsche Forschungsgemeinschaft (DFG; Germany)
- 2013 NIH; 2013/05 ACTS (Arthritis, Connective Tissue and Skin Study Section)
- 2013 NIH; Special Emphasis Panel: Dermatology, Rheumatology and Inflammation; ZRG1 MOSS T(03)
- 2013 NIH; Small Business Panel: Dermatology, Rheumatology and Inflammation; ZRG1 MOSS T(12)
- 2014 Action Medical Research (UK) C.V. Maranke I. Koster, Ph.D. 4
- 2014 Biotechnology and Biological Sciences Research Council (UK)
- 2014 Maimonide-Israel Research Program (Israel-France)
- 2015 NIH; 2016/01 ACTS (Arthritis, Connective Tissue and Skin Study Section)
- 2016 NIH; 2016/02 ACTS (Arthritis, Connective Tissue and Skin Study Section)
- 2016 National Science Center (Poland)
- 2016 Research Councils UK 2016 NYSTEM (New York State Stem Cell Science), Musculoskeletal and Skin panel
- 2017 NIH; ZRG1 MOSS-C(12) (Dermatology, Rheumatology and Inflammation)
- 2017 DEBRA International 2018 NSF; Graduate Research Fellowships (GRFP) – Cell Biology Panel
- 2018 NIH; Special Emphasis Panel

2018/05 ZRG1 F10B-B (20)

2018 NIH; Special Emphasis Panel 2018/10 ZRG1 F10B-B (20) L

2018 Center for the Advancement of Science in Space (CASIS)

2018 British Skin Foundation (UK)

2018, 2019 NSF; Graduate Research Fellowships (GRFP) – Cell Biology Panel

2018 NIH; Special Emphasis Panel

2018/05 ZRG1 F10B-B (20) 2019 VINMEC healthcare system Vietnam

2019 NIH; Special Emphasis Panel 2019/05 ZRG1 F05-U (20) M

2019 NIH; Special Emphasis Panel 2019/10 ZRG1 F05-U (20) M 2019 NIH; Small Business Panel 2020/01 ZRG1 MOSS-C (12) B

**Editorial Board:**

2013-2018 Member, Editorial Board of Experimental Dermatology

2014-2017 Member, Editorial Board of PLOS One

**Ad Hoc Reviewer:**

Ad hoc reviewer for journals

Journal of Investigative Dermatology, Journal of the European Academy of Dermatology and Venereology, Stem Cells, Dermatology Research and Practice, PLoSOne, Journal of Biological Chemistry, Molecular Biology of the Cell, Experimental Dermatology, Journal of Biomedicine and Biotechnology, American Journal of Medical Genetics, Apoptosis, Proceedings of the National Academy of Science USA, Journal of Cell Biology, Biochemical Pharmacology, Journal of Medical Case Reports, Cell Death and Differentiation, Journal of Clinical Investigation, Cell Death and Disease, Molecular Carcinogenesis, International Journal of Biological Sciences, Human Genetics, Journal of Dermatological Science, Clinical Genetics, Journal of Cell Science.

Ad hoc reviewer for scientific meetings

2007 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Zurich, Switzerland, September 5-8, 2007.

2008 Abstract reviewer for the International Investigative Dermatology (IID) Meeting, Kyoto, Japan, May 14-17, 2008.

2009 Abstract reviewer for the Annual Meeting of the Society of Investigative Dermatology (SID), Montreal, Canada, May 6-9, 2009.

2009 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Budapest, Hungary, September 9-12, 2009.

2010 Abstract reviewer for the Annual Meeting of the Society of Investigative Dermatology (SID), Atlanta, Georgia, May 5-8, 2010. C.V. Maranke I. Koster, Ph.D. 5

2010 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Helsinki, Finland, September 8-11, 2010.

2011 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Barcelona, Spain, September 7-10, 2011.

2012 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Venice, Italy, September 19-22, 2012.

Attachment E

2015 Abstract reviewer for Annual Meeting of the European Society for Dermatological Research (ESDR), Rotterdam, The Netherlands, September 9-12, 2015.

**Non-Appropriated Capital Improvement Project Procedures**  
**Board of Trustees Finance and Facilities Committee**  
**East Carolina University**  
**February 6, 2020**

**Purpose:**

The UNC Board of Governors has delegated authority to the Board of Trustees (BOT) to approve and administer non-appropriated capital improvement projects funded entirely with non-General Funds that are less than \$750,000.

**Requested Action:**

Request authority be delegated from the BOT to the Chancellor, in consultation with the Board of Trustees' Finance and Facilities Committee Chair, to approve non-General Fund repair and/or renovation projects whose cost is expected to be less than \$750,000 and report at each BOT meeting actions taken since the last meeting.

**Procedure:**

**Step 1 – Project Identification**

The initial step in capital project development is to define the project intent, scope and budget. Facilities Staff, in concert with the Department, accomplish this. Preliminary project approval is required from the appropriate Vice Chancellor funding the project.

**Step 2 – Approval**

Projects are presented to the Vice Chancellor for Administration and Finance and Chancellor, for Chancellor approval, in consultation with the Board of Trustees' Finance and Facilities Committee Chair. The Committee for Finance and Facilities and the full BOT are notified as projects are approved and are provided a list of approved projects at their next scheduled meeting.

**Step 3 – Submission**

The Vice Chancellor for Administration and Finance will submit approved projects to the UNC System Office for initiation and input into the State Interscope project management system.

**Background:**

Projects that cost less than \$750,000 are typically for smaller repairs or renovations funded by auxiliary units or carryforward funds. Many of these projects have short project timelines and happen over the summer, when the impact to campus is reduced. The BOT have delegated the selection of designers (informal and formal) to the VCAF. These selections are reported at each BOT meeting. This process would be similar with delegation to the Chancellor. As the BOT only meets five times per year, this limits the opportunity to have projects approved as timely as needed to maximize efficiency and achieve cost savings without this delegation.

**RESOLUTION OF  
THE BOARD OF TRUSTEES OF EAST CAROLINA UNIVERSITY**

**March 17, 2020**

WHEREAS, the State of North Carolina lacks an enacted budget for the FY 2019-2021 biennium; and

WHEREAS, East Carolina University serves over 28,000 students from all 100 counties of North Carolina, enrolls more students from rural areas than any UNC system campus, is graduating students at the fastest rate in our history, and employs more than 6,000 North Carolinians; and

WHEREAS, the current proposed budget, House Bill 966, includes funding for several critical and time-sensitive University and community investments, including but not limited to:

- \$215 million for a new medical education and research facility to replace the obsolete Brody School of Medicine building and support class-size expansion,
- \$850,000 in recurring and non-recurring funds for ECU's statewide telepsychiatry program,
- \$1 million to Eastern AHEC to further develop medical residency programs that support the retention of residency graduates in rural areas,
- \$2.5 million for a food commercialization center in Ayden,
- \$150,000 for a Bethel's water treatment facilities, and
- \$130 million in much needed repairs and renovations for UNC system campuses; and

WHEREAS, Senate Bill 354 provided approximately four percent raises over the next two years to university faculty and staff, who are critical to our mission to serve the state; and

WHEREAS, the absence of an enacted state budget for FY 19-21 hurts East Carolina University faculty, staff, students, and the communities we serve, and threatens the ability of the University to serve the citizens of the State and contribute to the economic vitality of North Carolina;

NOW, THEREFORE, BE IT RESOLVED, that the Board of Trustees of East Carolina University strongly encourages all members of the NC Senate who support and value the contributions of East Carolina University to the state of North Carolina and the world class higher educational systems in North Carolina to move swiftly to override the Governor's veto of House Bill 966. Additionally, we encourage the NC General Assembly to enact the provisions originally included in Senate Bill 354. Further, we call on boards and governing bodies of local and regional entities and organizations to create and approve a concurring resolution as soon as practical.

Adopted this 17<sup>th</sup> day of March, 2020.

---

Vern Davenport, Chairman